letrozole has been researched along with tamoxifen in 492 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (3.25) | 18.2507 |
| 2000's | 264 (53.66) | 29.6817 |
| 2010's | 181 (36.79) | 24.3611 |
| 2020's | 31 (6.30) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodie, A; Savinov, A; Wang, J; Yue, W | 1 |
| Enomoto, K | 1 |
| Buzdar, AU; Roseman, BJ; Singletary, SE | 1 |
| Dickson, RB; El-Ashry, D; Hannum, RS; Kern, FG; Kharbanda, S; Lopez, CA; Lorant, LA; McLeskey, SW; Tobias, CA; Trock, BJ; Zhang, L | 1 |
| Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, JP; Yue, W | 1 |
| Colussi, DM; Lefèvre, GY; Parisot, CY | 1 |
| Brodie, A; Liu, Y; Lu, Q; Wang, J; Yue, W | 1 |
| Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, J; Yue, W | 1 |
| Hamilton, A; Piccart, M | 1 |
| Dowsett, M; Ingle, JN; Johnson, PA; Jordan, VC; Krook, JE; Loprinzi, CL; Mailliard, JA; Perez, EA; Suman, VJ; Wheeler, RH | 1 |
| Dowsett, M; Gundacker, H; Houston, SJ; Johnston, SR; Miles, DW; Pfister, C; Sioufi, A; Smith, IE; Verbeek, JA | 1 |
| Brodie, A; Gimbel, M; Grigoryev, D; Liu, Y; Long, BJ; Lu, Q | 1 |
| Brodie, AM; Njar, VC | 1 |
| Dowsett, M | 1 |
| Bellamy, C; Cameron, DA; Dixon, JM; Leonard, RC; Love, CD; Miller, WR; Renshaw, L | 1 |
| Dowsett, M; Ingle, JN; Jordan, VC; Suman, VJ | 1 |
| Harvey, HA; Santen, RJ | 1 |
| Mokbel, K | 1 |
| Apffelstaedt, J; Bapsy, PP; Becquart, D; Boni, C; Chaudri-Ross, HA; Dank, M; Dugan, M; Gershanovich, M; Jänicke, F; Lassus, M; Monnier, A; Mouridsen, H; Pérez-Carrión, R; Pluzanska, A; Salminen, E; Sleeboom, HP; Smith, R; Snyder, R; Staffler, B; Sun, Y; Verbeek, JA | 1 |
| Tominaga, T | 1 |
| Pritchard, KI | 1 |
| Borgs, M; Brady, C; Coop, A; Dugan, M; Ellis, MJ; Evans, DB; Jänicke, F; Llombert-Cussac, A; Mauriac, L; Miller, WR; Quebe-Fehling, E; Singh, B | 1 |
| Lønning, PE | 2 |
| Murray, R | 1 |
| Nabholtz, JM; Reese, DM | 1 |
| Buzdar, AU | 6 |
| Fenaroli, P; Labianca, R; Tondini, C | 1 |
| Appfelstaedt, J; Borgs, M; Chaudri-Ross, HA; Dugan, M; Eiermann, W; Ellis, M; Eremin, J; Lassus, M; Llombart-Cussac, A; Mauriac, L; Paepke, S; Vinholes, J | 1 |
| Blankenstein, MA; Blijham, GH; Brodie, AM; Chen, T; DeJong, PC; Elbers, JR; Fulton, A; Long, BJ; Lu, Q; Macpherson, N; Nortier, JW; Schipper, ME; Slee, PH; Thijssen, JH; van de Ven, J; van Gorp, JM | 1 |
| Anderson, TJ; Cameron, DA; Dixon, JM; Miller, WR | 1 |
| Chen, G; Cohen, MH; Johnson, JR; Li, N; Pazdur, R | 1 |
| Timms, B | 1 |
| Goss, PE | 5 |
| Illiger, HJ | 1 |
| Jones, SE | 1 |
| Benedetto, C; De Nicola, B; Ferraris, F; Genta, F; Piccinno, R; Porpiglia, M; Vicelli, R | 1 |
| Alba, E; Colla, F; Farina, C; Mazzoleni, A; Ragonesi, G | 1 |
| Ingle, JN | 4 |
| Brodie, AM; Jelovac, D; Long, BJ; Thiantanawat, A | 1 |
| Bettuzzi, S; Filippi, S; Forti, G; Granchi, S; Ledda, F; Luconi, M; Maggi, M; Tozzi, P; Vignozzi, L | 1 |
| Atalay, G; Cardoso, F; Piccart, MJ | 1 |
| Anderson, TJ; Dixon, JM; Miller, WR | 1 |
| Robertson, JF | 1 |
| Crescioli, C; Ferruzzi, P; Forti, G; Granchi, S; Luconi, M; Maggi, M; Mancina, R; Muratori, M; Serio, M; Vannelli, GB | 1 |
| Martín de Vidales, C; Pérez-Torrubia, A; Zapatero, A | 1 |
| Jones, T; Karnon, J | 1 |
| Ali, SM; Brady, C; Carney, W; Chaudri-Ross, HA; Demers, L; Harvey, HA; Leitzel, K; Lipton, A; Wyld, P | 1 |
| Anderson, TJ; Cameron, D; Dixon, JM; Macfarlane, L; Miller, WR | 1 |
| Apffelstaedt, J; Bapsy, PP; Becquart, D; Bhatnagar, A; Boni, C; Chaudri-Ross, H; Dank, M; Gershanovich, M; Jaenicke, F; Lang, R; Monnier, A; Mouridsen, H; Perez-Carrion, R; Pluzanska, A; Salminen, E; Sleeboom, HP; Smith, R; Snyder, R; Sun, Y; Wyld, P | 1 |
| Berstein, LM; Harada, H; Lykkesfeldt, AE; Naftolin, F; Santen, RJ; Shanabrough, M; Wang, JP; Yue, W; Zheng, H | 1 |
| Dranitsaris, G; Trudeau, M; Verma, S | 1 |
| Höffken, K; Sayer, HG | 1 |
| Rose, C | 1 |
| Brodie, AH; Mouridsen, HT | 1 |
| Dowsett, M; Ellis, MJ | 1 |
| Thomas, R | 1 |
| Dixon, JM; Jackson, J; Miller, WR | 1 |
| Bryant, J; Wolmark, N | 1 |
| Burstein, HJ | 1 |
| Abrams, JS; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Therasse, P; Tu, D | 1 |
| Chaudri-Ross, HA; Coop, A; Ellis, MJ; Evans, DB; Jänicke, F; Llombart-Cussac, A; Mauriac, L; Miller, WR; Quebe-Fehling, E; Singh, B; Tao, Y | 1 |
| Glendenning, A; Johnston, SR; Jones, T; Karnon, J | 1 |
| Hobson, K | 1 |
| Brodie, AH; Jelovac, D; Long, B | 1 |
| Smith, IE | 3 |
| Dixon, JM; Jackson, J; Miller, WR; Renshaw, L | 1 |
| Dressman, H; Ellis, MJ; Marks, J; Rosen, E | 1 |
| Jones, J; Kirma, N; Luthra, R; Tekmal, RR | 1 |
| Twombly, R | 1 |
| Brodie, AH; Mouridsen, HT; Rose, C; Smith, IE | 1 |
| Filippi, S; Forti, G; Gelmini, S; Granchi, S; Ledda, F; Luconi, M; Maggi, M; Mancina, R; Marini, M; Morelli, A; Orlando, C; Vannelli, GB; Vignozzi, L | 1 |
| DeGrendele, H | 1 |
| Shahab, N | 1 |
| Harris, SR | 1 |
| Hellman, D; Hellman, S | 1 |
| Domont, J; Khayat, D; Namer, M; Spano, JP | 1 |
| Kawakami, M; Saji, S; Toi, M | 1 |
| Ellis, MJ | 1 |
| Dixon, JM | 2 |
| Brodie, AM; Goloubeva, OG; Handratta, V; Jelovac, D; Long, BJ; MacPherson, N; Ragaz, J; Thiantanawat, A | 1 |
| Campos, SM | 1 |
| Armeanu, S; Fersis, N; Friedrich, M; Gagulic, E; Pantic, L; Relakis, K; Smyczek-Gargya, B; Wallwiener, D | 1 |
| Altundag, K; Oyan, B; Ozisik, Y | 1 |
| Arora, A; Potter, JF | 1 |
| Chaudri-Ross, HA; Mouridsen, HT | 1 |
| Clemons, M; Coleman, RE; Verma, S | 1 |
| Sainsbury, R | 1 |
| Ellis, M | 1 |
| Aglietta, M; Cirillo, S; Gatti, M; Martincich, L; Montemurro, F; Regge, D; Russo, F | 1 |
| Aebi, S; Baumann, ChK | 1 |
| Tobias, JS | 1 |
| Barrett, JC; Berrigan, D; Brodie, A; Hursting, SD; Jelovac, D; Macedo, L; Núñez, NP; Perkins, SN | 1 |
| Altundag, K; Buzdar, AU; Hortobagyi, G; Morandi, P; Rouzier, R; Theriault, RL | 1 |
| Becquart, D; Chaudri-Ross, HA; Gershanovich, M; Lang, R; Mouridsen, H; Perez-Carrion, R; Sun, Y | 1 |
| Chaudri-Ross, HA; Mouridsen, H | 1 |
| Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I | 1 |
| Davis, GJ; Ravdin, PM | 1 |
| Caruggi, M; Colombo, G; Marchetti, M | 1 |
| Brodie, AM; Goloubeva, OG; Handratta, V; Ingle, JN; Jelovac, D; Long, BJ; Macedo, L | 1 |
| de Cremoux, P; Diéras, V; Fourquet, A; Magdelénat, H; Pierga, JY; Poupon, MF; Sigal-Zafrani, B | 1 |
| Harwood, KV | 1 |
| Fentiman, IS | 1 |
| Clemons, MJ; Freedman, OC; Verma, S | 1 |
| Henderson, IC | 1 |
| Fricker, J | 2 |
| Kondo, M; Miki, S; Ochiai, T; Okubo, I; Toi, M | 1 |
| Kahán, Z | 1 |
| Deangelis, D; Goss, PE; Heath, M; Ingle, JN; Liu, S; Palmer, MJ; Perez, EA; Pritchard, PH; Shepherd, L; Tu, D; Wasan, KM | 1 |
| Akar, M; Buyuk, E; Libertella, N; Oktay, K; Rosenwaks, Z | 1 |
| Liu, H; Mi, Y; Tang, X; Zeng, W; Zhang, C | 1 |
| Chen, S; Itoh, T; Karlsberg, K; Kijima, I; Smith, D; Ye, J; Yuan, YC | 1 |
| Dodwell, D; Vergote, I | 1 |
| Oktay, K | 1 |
| Carpi, A; Nicolini, A | 1 |
| Kaufmann, M; Rody, A | 2 |
| Ingle, JN; Suman, VJ | 1 |
| Cole, B; Gard, C; Glendenning, GA; Irish, W; Mouridsen, H; Sherrill, B | 1 |
| Ali, SM; Carney, W; Chaudri-Ross, HA; Demers, L; Evans, D; Hackl, W; Hamer, P; Harvey, HA; Lang, R; Leitzel, K; Lipton, A | 1 |
| Brodie, AM; Goloubeva, OG; Jelovac, D; Long, BJ; Macedo, L; Sabnis, G | 1 |
| Brodie, AM; Goloubeva, OG; Handratta, V; Jelovac, D; Macedo, L | 1 |
| Brodie, A; Goloubeva, O; Jelovac, D; Long, B; Macedo, L; Sabnis, G | 1 |
| Senn, HJ; Thürlimann, B | 1 |
| Hamilton, AL; Nordman, IC; Spillane, AJ | 1 |
| Bae, K; Ellis, M; Klause, A; Tao, Y; Vickers, A | 1 |
| Anderson, TJ; Dixon, JM; Evans, D; Krause, A; Larionov, A; Miller, WR; Murray, J; White, S | 1 |
| Gradishar, WJ | 1 |
| Johnson, JR; Kelly, R; Mann, BS; Pazdur, R; Sridhara, R; Williams, G | 1 |
| Abrams, JS; Cameron, DA; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D | 5 |
| Goss, PE; Ingle, JN; Liu, S; Martino, S; Muss, HB; Palmer, M; Pater, JL; Pritchard, K; Robert, NJ; Shepherd, LE; Tu, D; Whelan, TJ | 1 |
| Oktay, KH | 1 |
| Chen, S; Itoh, T; Kijima, I | 1 |
| Dörken, B; Kretzschmar, A; Lindner, T; Mrozek, A; Pink, D; Reichardt, P; Thuss-Patience, PC | 1 |
| Koeberle, D; Thuerlimann, B | 2 |
| Castiglione-Gertsch, M; Coates, AS; Forbes, JF; Gelber, RD; Goldhirsch, A; Keshaviah, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B; Wardley, A; Wardly, A | 1 |
| Swain, SM | 1 |
| Davis, WA; Dokras, A; Moss, V; Ryan, GL; Sparks, AE; Van Voorhis, BJ | 1 |
| Fodor, J | 1 |
| Brandman, J; Delea, T; Goss, PE; Johnston, SR; Karnon, J; Smith, R; Sung, J | 1 |
| Gltick, S | 1 |
| Keam, SJ; Scott, LJ | 1 |
| Higa, GM | 1 |
| Hargis, JB; Nakajima, ST | 1 |
| Abrial, C; Cabrespine, A; Chollet, P; Cure, H; Durando, X; Ferriere, JP; Kwiatkowski, F; Leheurteur, M; Mouret-Reynier, MA; Penault-Llorca, F | 1 |
| Wardley, AM | 2 |
| Baum, M; Buzdar, AU; Cuzick, J | 1 |
| Erban, JK | 1 |
| Chlebowski, RT | 1 |
| Grana, G | 1 |
| Dunn, C; Keam, SJ | 1 |
| Forbes, JF | 1 |
| Dowsett, M; Hayes, D; Lønning, PE; Santen, RJ; Smith, IE; Walsh, G; Yap, YS | 1 |
| Canorea, F; Del Castillo, A; Gil, JM; González, P; Rubio-Terrés, C | 1 |
| Duffy, MJ | 1 |
| Tsukagoshi, S | 1 |
| Brown, MM; Manquez, ME; Shields, CL; Shields, JA | 1 |
| Brandman, J; Delea, T; El Ouagari, K; Karnon, J; Talbot, W | 1 |
| Findlay, BP; Goss, PE; Ingle, JN; Josse, RG; Liu, S; Martino, S; Palmer, MJ; Perez, EA; Pritchard, KI; Shenkier, TN; Shepherd, LE; Tozer, RG; Tu, D | 1 |
| Brandman, J; Delea, TE; Gross, PE; Johnston, SR; Karnon, J; Smith, RE; Sung, JC | 1 |
| Vakaet, L | 1 |
| Brodie, AM; Nnane, IP; Tao, X | 1 |
| Goss, PE; Ingle, JN; Moy, B; Pater, JL; Shepherd, LE; Tu, D; Whelan, TJ | 1 |
| Crane, J; Gaya, A; Stebbing, J | 1 |
| Bryce, C; Chia, SK; Gelmon, KA; Kennecke, HF; Norris, B; Olivotto, IA; Speers, C | 1 |
| Borenstein, MR; Canney, DJ; Nnane, IP; Piao, H; Tao, X | 1 |
| Ali, SM; Carney, W; Chaudri-Ross, HA; Demers, L; Evans, DB; Hackl, W; Hamer, P; Leitzel, K; Lipton, A; Souder, C | 1 |
| DiLeonardo, M; Gibbons, G; Resnik, KS | 1 |
| Brodie, A; Jelovac, D; Sabnis, G | 1 |
| Beresford, MJ; Makris, A; Ravichandran, D | 1 |
| Goss, PE; Gottardt, H; Ingle, JN; Olson, JE; Scott, CG; Suman, VJ; Vachon, CM | 1 |
| Barash, NIu; Bershteĭn, LM; Gamaiunova, VB; Ivanov, VG; Kovalenko, IG; Malysheva, SA; Poroshina, TE; Semiglazov, VF; Shcherbakova, EB; Tsyrlina, EV; Zhil'tsova, EK | 1 |
| Castiglione-Gertsch, M; Chirgwin, J; Coates, AS; Colleoni, M; Del Mastro, L; Forbes, JF; Gelber, RD; Goldhirsch, A; Jakobsen, EH; Keshaviah, A; Láng, I; Mauriac, L; Mouridsen, H; Nogaret, JM; Paridaens, R; Pienkowski, T; Price, KN; Smith, I; Thürlimann, B; Wardley, A | 1 |
| Dewar, R; Rayson, D; Skedgel, C; Younis, T | 1 |
| Costantino, J; Cronin, W; Geyer, C; Harkins, B; Jeong, JH; Lembersky, B; Mamounas, EP; Paik, S; Wickerham, DL; Wolmark, N | 1 |
| Imai, H; Kuroi, K; Ohsumi, S; Ono, M; Shimozuma, K | 1 |
| Castiglione-Gertsch, M; Coates, AS; Debled, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Keshaviah, A; Láng, I; Mauriac, L; Monnier, A; Mouridsen, H; Nogaret, JM; Paridaens, R; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B; Viale, G; Wardley, A; Zabaznyi, N | 1 |
| Nortier, JW; Seynaeve, C; van de Velde, CJ; van Nes, JG | 1 |
| Mouridsen, HT | 2 |
| Konkle, AT; McCarthy, MM; Schwarz, JM; Shiroor, C; Speert, DB; Taylor, ME; Zup, SL | 1 |
| Angeli, A; Ardine, M; Berruti, A; Bertoldo, F; Dogliotti, L; Mosca, A; Tucci, M; Vana, F | 1 |
| Lian, ZQ; Yang, MT | 1 |
| Aapro, M; Cannon, H; Georgiou, V; Leto di Priolo, S; Wengström, Y | 1 |
| Brodie, A; Goloubeva, O; Jelovac, D; Sabnis, G; Schayowitz, A | 1 |
| Monnier, AM | 1 |
| Kafy, S; Tulandi, T | 1 |
| Barghout, V; Delea, TE; Karnon, J; Papo, NL; Sofrygin, O; Thomas, SK | 1 |
| Barghout, V; Delea, T; Karnon, J | 1 |
| Carroll, C; De Nigris, E; Hind, D; Simpson, E; Ward, S; Wyld, L | 1 |
| Delea, TE; El-Ouagari, K; Karnon, J; Sofrygin, O | 1 |
| Braye, S; Castiglione-Gertsch, M; Coates, AS; Dell'Orto, P; Gelber, RD; Goldhirsch, A; Gusterson, BA; Maiorano, E; Mastropasqua, MG; Neven, P; Ohlschlegel, C; Orosz, Z; Price, KN; Raffoul, J; Rasmussen, BB; Regan, MM; Thürlimann, B; Viale, G | 1 |
| Abreu, P; Banke-Bochita, J; Goss, PE; Hadji, P; Subar, M; Thomsen, T | 1 |
| Cao, A; Zhang, C | 1 |
| Kamby, C; Lindberg, H; Nielsen, DL; Tuxen, M | 1 |
| Cufer, T | 1 |
| Fabian, CJ | 1 |
| Bhatnagar, AS | 1 |
| Ellis, MJ; Ma, C | 1 |
| O'Shaughnessy, J | 1 |
| Perez, EA | 1 |
| Haidinger, R; Harbeck, N | 1 |
| Jahanzeb, M | 1 |
| Atabekoglu, C; Sonmezer, M | 1 |
| Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Keshaviah, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Rabaglio, M; Smith, I; Sun, Z; Thürlimann, B | 1 |
| Dodwell, D; Williamson, D | 1 |
| Altermatt, HJ; Braye, S; Castiglione-Gertsch, M; Coates, AS; Del Curto, B; Dell'Orto, P; Gelber, RD; Goldhirsch, A; Gusterson, BA; Henriksen, KL; Lacroix-Triki, M; Lykkesfeldt, AE; Mastropasqua, MG; Méry, E; Price, KN; Rasmussen, BB; Regan, MM; Thürlimann, B; Viale, G | 1 |
| Botti, G; D'Aiuto, G; D'Aiuto, M; De Maio, E; de Matteis, A; Di Rella, F; Esposito, G; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rinaldo, M; Rossi, E | 1 |
| Eisen, A; Messersmith, H; Pritchard, KI; Shelley, W; Trudeau, M | 1 |
| Collingridge, D | 1 |
| Blackwell, KL; Herold, CI | 2 |
| Doughty, JC | 2 |
| Carpenter, R | 1 |
| Braat, S; Gerhard, D; Hothorn, LA | 1 |
| Castiglione-Gertsch, M; Chirgwin, JH; Coates, AS; Colleoni, M; Crivellari, D; Del Mastro, L; Forbes, JF; Gelber, RD; Gladieff, L; Goldhirsch, A; Láng, I; Mauriac, L; Mouridsen, H; Paridaens, RJ; Price, KN; Rabaglio, M; Smith, IE; Sun, Z; Thürlimann, B | 1 |
| Goss, PE; He, Z; Ingle, JN; Martino, S; Muss, HB; Palmer, MJ; Pater, JL; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D; Whelan, TJ | 1 |
| Aapro, M | 1 |
| Pennery, E | 1 |
| A'Hern, RP; Cameron, DA; Dixon, JM; Dowsett, M; Folkerd, E; Macaskill, EJ; McHugh, M; Murray, J; Renshaw, L; Young, O | 1 |
| Marshall, C; Thomas, R; Walker, L; Williams, M | 1 |
| Ali, SM; Brown-Shimer, S; Carney, W; Chaudri-Ross, HA; Demers, L; Evans, DB; Gaur, V; Hamer, P; Leitzel, K; Lipton, A; Pierce, K | 1 |
| Adrover, E; Barnadas, A; Calvo, L; de la Haba, J; Estevez, LG; Gil, M; Llombart, A; Sánchez-Rovira, P | 1 |
| Fields, MM; Mellington, TE | 1 |
| Gligorov, J; Nabholtz, JM | 1 |
| Chen, S; Lui, K; Mori, T; Tamura, T; Zhou, D | 1 |
| Paydas, S | 1 |
| Vaidya, JS | 1 |
| Nagykálnai, T | 1 |
| A'Hern, R; Bhatnagar, AS; Chaudri Ross, HA; Dowsett, M; Eiermann, W; Ellis, MJ; Evans, DB; Luo, J; Miller, WR; Smith, I; Tao, Y; von Kameke, A | 1 |
| Chaudri Ross, HA; Ellis, MJ; Evans, DB; Miki, Y; Miller, WR; Sasano, H; Suzuki, T; Tao, Y | 1 |
| Harbeck, N | 1 |
| Braye, SG; Castiglione-Gertsch, M; Coates, AS; Dell'Orto, P; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Gusterson, BA; Knox, F; MacGrogan, G; Maiorano, E; Mastropasqua, MG; Neven, P; Ohlschlegel, C; Olszewski, WP; Orosz, Z; Price, KN; Regan, MM; Thürlimann, B; Viale, G | 1 |
| Dos Reis, FJ; Ferriani, RA; Filho, FM; Martins, WP; Nastri, CO | 1 |
| Cianfrocca, M | 1 |
| Ejlertsen, B; Henriksen, KL; Lykkesfeldt, AE; Mouridsen, HT; Møller, S; Rasmussen, BB | 1 |
| Alberts, S; Dentchev, T; Hines, SL; Johnson, DB; Kahanic, S; Liu, H; Loprinzi, CL; Mazurczak, MA; Mincey, B; Nikcevich, DA; Perez, EA; Schaefer, PL; Sloan, JA | 1 |
| Campbell, I; Colleoni, M; Gelber, RD; Goldhirsch, A; Price, KN; Ravaioli, A; Simoncini, E; Sun, Z; Towler, M | 1 |
| Azria, D; Belkacémi, Y; Gligorov, J; Jacot, W; Ozsahin, M; Romieu, G; Zaman, K | 1 |
| Aliev, DA; Azizov, VA; Musaev, IN; Sadygova, TA; Zeĭnalov, RS | 1 |
| Botti, G; Chiodini, P; D'Aiuto, G; De Feo, G; De Maio, E; de Matteis, A; Di Maio, M; Di Rella, F; Esposito, G; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rossi, E | 1 |
| Sun, L; Wang, Z; Zha, J | 1 |
| Campone, M; Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Hawle, H; Láng, I; Mouridsen, H; Nogaret, JM; Paridaens, RJ; Pienkowski, T; Price, KN; Rabaglio, M; Smith, I; Sun, Z; Thürlimann, B | 1 |
| Gelber, RD; Giobbie-Hurder, A; Price, KN | 1 |
| Fischgräbe, J; Götte, M; Kiesel, L; Radke, I; Smollich, M; Wülfing, P | 1 |
| Ejlertsen, B; Evans, DB; Henriksen, KL; Lykkesfeldt, AE; Mouridsen, HT; Møller, S; Rasmussen, BB; Sasano, H | 1 |
| Calado, RT; Kajigaya, S; Regal, JA; Stratakis, CA; Wilkerson, KL; Yewdell, WT; Young, NS | 1 |
| Anderson, J; Chen, YY; Chin, K; DeVries, S; Esserman, LJ; Hwang, ES; Lessing, J; Shim, V; Swain, R; Waldman, FM | 1 |
| Coates, AS; Forbes, J; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Regan, MM; Smith, I; Thürlimann, B | 1 |
| Amakye, D; Bauerfeind, I; Buzdar, A; Chia, S; Chlebowski, R; Cutuli, B; Cuzick, J; Hadji, P; Linforth, R; Maass, N; Noguchi, S; Robidoux, A; Verma, S | 1 |
| Glück, S | 1 |
| Lazarus, P; Sun, D | 1 |
| Chen, S; Masri, S; Phung, S; Wang, X | 1 |
| Joerger, M; Thürlimann, B | 1 |
| Dixon, JM; Hannon, R; Macaskill, EJ; McCaig, FM; McHugh, M; Murray, J; Renshaw, L; Williams, L; Young, O | 1 |
| Aogi, K; Hara, F; Kiyoto, S; Osumi, S; Takabatake, D; Takashima, S | 1 |
| Chetty, U; Wishart, GC | 1 |
| Fu, Z; Jin, Y; Liu, W; Qian, H; Shao, X; Sun, L; Wen, L | 1 |
| Recht, A | 1 |
| Morimoto, N; Shibaki, T | 1 |
| Bernhard, J; Cardoso, F; Coates, AS; Gelber, RD; Goldhirsch, A; Harvey, V; Pagani, O; Phillips, KA; Price, KN; Ribi, K; Stephens, A; Sun, Z; Thompson, A; Thürlimann, B | 1 |
| Dowsett, M; Evans, AH; Evans, DB; Farmer, I; Johnston, SR; Martin, LA; Pancholi, S; Thornhill, A | 1 |
| Hyspler, R; Kalábová, H; Kasparová, M; Krcmová, L; Melichar, B; Plísek, J; Solichová, D; Studentová, H | 1 |
| Agrawal, K; Mortimer, JE; Onami, S; Pal, SK | 1 |
| Beer, B; Hubalek, M; Meraner, V; Oberacher, H; Oberguggenberger, A; Schubert, B | 1 |
| Dixon, JM; Dixon, OM; Fallowfield, LJ; Langridge, C; Macaskill, EJ; McCaig, F; McHugh, M; Murray, J; Renshaw, L; Williams, L; Young, OE | 1 |
| Bonetti, M; Cole, BF; Gelber, RD; Lazar, AA | 1 |
| Aldridge, J; Bernhard, J; Cardoso, F; Coates, AS; Gelber, RD; Goldhirsch, A; Harvey, V; Pagani, O; Phillips, KA; Price, KN; Ribi, K; Sun, Z; Thompson, A; Thürlimann, B | 1 |
| Oktay, K; Rodriguez-Wallberg, KA | 1 |
| Tang, SC | 1 |
| Chakravarty, D; Challa, R; Cortez, V; Nair, BC; Tekmal, RR; Vadlamudi, RK; Vallabhaneni, S | 1 |
| Christiaens, MR; De Smet, L; Dieudonné, AS; Henry, NL; Leunen, K; Lintermans, A; Morales, L; Neven, P; Pans, S; Paridaens, R; Timmerman, D; Van Calster, B; Van Hoydonck, M; Vergote, I; Verhaeghe, J; Verschueren, K; Westhovens, R; Wildiers, H | 1 |
| Chi, J; Fu, Z; Hu, X; Jin, Y; Shao, X; Sun, L | 1 |
| Chirgwin, J; Coates, AS; Colleoni, M; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Láng, I; Mauriac, L; Mouridsen, H; Paridaens, R; Pienkowski, T; Price, KN; Regan, MM; Smith, I; Thürlimann, B; Wardley, A | 1 |
| Coates, AS; Colleoni, M; Dell'Orto, P; Forbes, JF; Gelber, RD; Goldhirsch, A; Gusterson, BA; Láng, I; MacGrogan, G; Maiorano, E; Mastropasqua, MG; Mauriac, L; Mouridsen, H; Paridaens, RJ; Price, KN; Rasmussen, BB; Regan, MM; Thürlimann, B; Viale, G | 1 |
| Anderson, H; Arteaga, CL; Balko, JM; Dowsett, M; Dunbier, A; Ghazoui, Z; González-Angulo, AM; Miller, TW; Miller, WR; Mills, GB; Shyr, Y; Wu, H | 1 |
| Bu, H; Ni, YB; Yang, WJ; Zheng, H | 1 |
| Gelber, RD; Giobbie-Hurder, A; Price, KN; Regan, MM; Thürlimann, B | 1 |
| Cushman, M; Flockhart, DA; Lu, WJ; Mayhoub, AS; Pei, Z; Xu, C | 1 |
| Bonnefoi, H; Chirgwin, J; Coates, AS; Ejlertsen, B; Goldhirsch, A; Price, KN; Regan, MM; Smith, I; Sun, Z; Thürlimann, B | 1 |
| Champ, C; Gower-Thomas, K; Jones, M; Osborn, G; Vaughan-Williams, E | 1 |
| Chi, J; Fu, Z; Hu, X; Jin, Y; Shao, X; Sun, L; Ye, W | 1 |
| Amador, DD; Font López, KC; Novoa Vargas, A | 1 |
| Aebi, S; Berthod, G; Brauchli, P; Genton, C; Giobbie-Hurder, A; Huober, J; Lüthi, J; Pagani, O; Schönenberger, A; Simcock, M; Thürlimann, B; Zaman, K | 1 |
| Iwaki, M; Mizumoto, K; Naito, E; Takeyama, M; Zako, M | 1 |
| Coates, AS; Ejlertsen, B; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Láng, I; Mauriac, L; Neven, P; Price, KN; Rabaglio, M; Regan, MM; Smith, I; Thürlimann, B; Wardley, A | 1 |
| Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K | 1 |
| Brodie, A; Carboni, JM; Finckenstein, FG; Gottardis, MM; Greer, A; Haluska, P; Harrington, SC; Hou, X; Huang, F; Macedo, LF; Reeves, KA | 1 |
| Goss, PE; Jin, H; Shepherd, LE; Tu, D; Zhao, N | 1 |
| Barnadas, A; Estévez, LG; Lluch-Hernández, A; Rodriguez-Lescure, A; Rodriguez-Sanchez, C; Sanchez-Rovira, P | 1 |
| Evans, DB; Hayashi, S; Kataoka, M; Kondoh, K; Mori, K; Moriya, Y; Sawada, N; Yamaguchi, Y; Yasuno, H | 1 |
| Cohen, MH; Johnson, JR; Justice, R; Pazdur, R | 1 |
| Bernstein-Molho, R; Geffen, DB; Greenberg, J; Inbar, MJ; Pelles-Avraham, S; Safra, T; Sarid, D; Stemmer, SM; Stephansky, I | 1 |
| Bell, LN; Desta, Z; Flockhart, DA; Hayes, DF; Henry, NL; Li, L; Nguyen, AT; Stearns, V; Storniolo, AM; Wolff, AC | 1 |
| Burstein, HJ; Griggs, JJ | 1 |
| Biasi, MO; Bouzyk, M; Coates, AS; Debled, M; Dell'orto, P; Ditzel, HJ; Gelber, RD; Goldhirsch, A; Kammler, R; Leyland-Jones, B; Lyng, MB; Maibach, R; Neven, P; Pagani, O; Price, KN; Rae, JM; Regan, MM; Tang, W; Thürlimann, B; Viale, G | 1 |
| Kelly, CM; Pritchard, KI | 1 |
| Bartiromo, A; Botti, G; Buonfanti, G; Colantuoni, G; D'Aiuto, M; D'Aniello, R; Daniele, G; De Feo, G; De Laurentiis, M; De Maio, E; de Matteis, A; Di Bonito, M; Di Maio, M; Di Rella, F; Esposito, G; Gallo, C; Giordano, P; Gravina, A; Labonia, V; Landi, G; Lastoria, S; Maiolino, P; Morabito, A; Normanno, N; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rossi, E; Signoriello, S; Tinessa, V | 1 |
| Bell, KE; Burich, RA; DeGregorio, M; Greenberg, BE; Griffey, S; Gutierrez, A; McCall, JL; Mehta, NR; Wolf, M; Wurz, GT | 1 |
| Aldridge, J; Bernhard, J; Cardoso, F; Coates, AS; Gelber, RD; Goldhirsch, A; Harvey, V; Pagani, O; Phillips, KA; Price, KN; Ribi, K; Thompson, A; Thürlimann, B | 1 |
| Ito, Y | 1 |
| Aogi, K; Fujisawa, T; Fukuda, H; Inoue, K; Iwata, H; Kinoshita, T; Masuda, N; Nakamura, K; Shibata, T; Shien, T | 1 |
| Bjerre, K; Ejlertsen, B; Giobbie-Hurder, A; Henriksen, KL; Laenkholm, AV; Larsen, MS; Lykkesfeldt, AE; Rasmussen, BB | 1 |
| Alimirah, F; Gupta, A; Mehta, R; Mehta, RG; Murillo, G; Peng, X; Wiehle, R | 1 |
| Acar, H; Ata, O; Toy, H; Yavas, C; Yavas, G; Yuce, D | 1 |
| Moramazi, F; Nikbakht, R; Pourmatroud, E; Zargar, M | 1 |
| Cameron, DA; Chavarri-Guerra, Y; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Perez, EA; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D; Whelan, T | 1 |
| Bonnefoi, H; Coates, AS; Colleoni, M; Ejlertsen, B; Ewertz, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Gray, KP; Láng, I; Mouridsen, HT; Paridaens, RJ; Price, KN; Rabaglio, M; Regan, MM; Smith, IE; Thürlimann, B | 1 |
| Singh, AK | 1 |
| A'Hern, R; Dowsett, M; Evans, DB; Farmer, I; Ghazoui, Z; Guest, S; Johnston, SR; Lane, HA; Martin, LA; Pancholi, S; Ribas, R; Thornhill, AM; Weigel, MT | 1 |
| Goss, PE; Ingle, JN; Pritchard, PH; Shepherd, L; Tu, D; Wasan, KM | 1 |
| Goss, PE; Higgins, MJ; Liedke, PE | 1 |
| Armstrong, AC; Lee, RJ; Wardley, AM | 1 |
| Tung, N | 1 |
| Avsar, AF; Ide, T; Keles, H; Keskin, HL; Sirin, YS; Turgut, O | 1 |
| Aapro, M; Bartlett, JM; Coleman, RE; Markopoulos, C; Putter, H; van de Velde, CJ | 1 |
| Brauch, H; Precht, JC; Saladores, PH; Schroth, W; Schwab, M | 1 |
| Li, JH; Zeng, ZJ; Zhang, YJ; Zhao, ST | 1 |
| Buzdar, A; Gonzalez-Angulo, A; Hortobagyi, G; Litton, J; Mac Gregor, MC | 1 |
| Davies, C; Gray, R; Pan, H; Peto, R | 1 |
| Cetin, I; Topcul, F; Topcul, M | 1 |
| Ravichandran, D; Wylie, S | 1 |
| Barba, M; Del Medico, P; Di Lauro, L; Giannarelli, D; Laudadio, L; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Tomao, S; Vici, P | 1 |
| Gopal, G; Rajkumar, T; Rawat, A; Selvaluxmy, G | 1 |
| Badovinac-Crnjevic, T; Fan, L; Goss, PE; Strasser-Weippl, K | 1 |
| Goldhirsch, A | 1 |
| Goodwin, PJ | 1 |
| Mehta, A; Tripathy, D | 1 |
| Balkenende, E; Dahhan, T; Goddijn, M; Linn, S; van Wely, M | 1 |
| Bulun, SE; Khan, SA; Lin, Z; Moy, I; Rademaker, AW; Reierstad, S | 1 |
| Beketić-Orešković, L; Kasum, M; Orešković, S; Šimunić, V | 1 |
| Bonnefoi, H; Coates, AS; Cole, BF; Colleoni, M; Ejlertsen, B; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Huober, J; Láng, I; Neven, P; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B; Wardley, A; Wu, J | 1 |
| Boyle, F; Bulsara, M; Holman, CD; Kemp, A; Malacova, E; Preen, DB; Roughead, EE; Saunders, C | 1 |
| Ansari, A; Kumar, D; Singh, AK; Srivastava, PP; Srivastava, SC; Verma, R | 1 |
| Cutress, RI; Layfield, DM; Mohamud, M; Odofin, O; Royle, GT; Walsh, C | 1 |
| Aebi, S; Campone, M; Coates, AS; Debled, M; Decensi, A; Gelber, RD; Goldhirsch, A; Guerrieri-Gonzaga, A; Johansson, H; McIntosh, C; Monnier, A; Price, KN; Schönenberger, A; Sun, Z; Thürlimann, B; Tondini, C; Zaman, K | 1 |
| Carpi, A; Ferrari, P; Nicolini, A; Rossi, G | 1 |
| Angelucci, D; Ausili Cefaro, G; Cianchetti, E; Cioffi, P; De Tursi, M; Di Nicola, M; Grassadonia, A; Grossi, S; Iacobelli, S; Iezzi, L; Marinelli, C; Natoli, C; Noccioli, P; Politi, R; Tavoletta, S; Tinari, N; Zilli, M | 1 |
| A'Hern, R; Afentakis, M; Arnedos, M; Dowsett, M; Drury, S; Hills, M; Reis-Filho, JS; Salter, J; Smith, IE | 1 |
| Chene, G; Clemenson, A; Lacoste, CR; Lecointre, R; Lima, S; Peoc'h, M; Trombert, B | 1 |
| Schiavon, G; Smith, IE; Yeo, B | 1 |
| Aguilar, H; Balart, J; Barril, X; Beijersbergen, RL; Bonifaci, N; Bostner, J; Brunet, J; Burnstein, KL; Bustelo, XR; Caizzi, L; Carlson, KE; Clarke, R; Climent, F; Di Croce, L; Esteller, M; Extremera, AI; Figueras, A; Fornander, T; García, N; Garcia-Mata, R; Gil, M; Gómez-Baldó, L; Halonen, P; Islam, A; Jansen, MP; Karlsson, E; Katzenellenbogen, JA; Kiyotani, K; Martrat, G; Mushiroda, T; Nakamura, Y; Nevedomskaya, E; Pérez Tenorio, G; Pujana, MA; Rodríguez-Peña, AB; Rodríguez-Vida, A; Serra-Musach, J; Sgroi, DC; Soler, MT; Stål, O; Urruticoechea, A; Villanueva, A; Vizoso, M; Zembutsu, H; Zwart, W | 1 |
| Dryden, R; Harrow, A; McCowan, C; Parsons, M; Radley, A; Thompson, AM; Wells, M | 1 |
| Asensio, SN; Boni, C; Cavazza, A; Damiani, S; Gnoni, R; Lococo, F; Pagano, M; Rapicetta, C; Zanelli, F | 1 |
| Batra, U; Doval, DC; Dutta, K; Talwar, V | 1 |
| Barry, W; Block, CC; Borges, V; DeSantis, SD; Guo, H; Partridge, AH; Ruddy, KJ; Winer, EP | 1 |
| Agarwal, V; Cawkwell, L; Drew, PJ; Fox, JN; Garimella, V; Hussain, T; Kneeshaw, PJ; Lind, MJ; Long, ED; Mahapatra, TK; McManus, PL; Radhakrishna, S | 1 |
| Billen, J; Christiaens, MR; Jans, I; Laenen, A; Lintermans, A; Neven, P; Paridaens, R; Pauwels, S; Van Asten, K; Van Herck, E; Vanderschueren, D; Verhaeghe, J; Vermeersch, P; Wildiers, H | 1 |
| Albertini, S; Kelly, E; Lu, CY; Vitry, A | 1 |
| Abehsera, D; de Santiago, J; Panal, M; Revello, R; Sánchez-Mendez, JI; Zapardiel, I | 1 |
| Al-Kharboosh, R; Alamri, A; Axelrod, ML; Bouker, KB; Clarke, R; Dabydeen, SA; Díaz-Cruz, ES; Furth, PA; Hennighausen, L; Kang, K | 1 |
| Lukina, NA; Nekrasova, AA; Smirnov, AF; Trukhina, AV; Vakkerov-Kouzova, ND | 1 |
| Atkins, L; Barni, S; Deschamp, V; Franquet, A; Gnant, M; Kreienberg, R; Markopoulos, C; Marty, M; Neciosup, S; Neven, P; Tanner, M; Tesarova, P | 1 |
| Hansen, SK; Hole, S; Lundqvist, J; Lykkesfeldt, AE; Pedersen, AM; Yde, CW | 1 |
| Blok, EJ; Derks, MG; Kroep, JR; van de Velde, CJ; van der Hoeven, JJ | 1 |
| Barbie, TU; Ma, C; Margenthaler, JA | 1 |
| Dakhil, SR; Hines, SL; Kearns, AE; Lafky, JM; Liu, H; Loprinzi, CL; Perez, EA; Puttabasavaiah, S; Sloan, JA; Wagner-Johnston, ND | 1 |
| Chang, CH; Chen, SJ; Liu, CY | 1 |
| Antolín-Novoa, S; Antón, A; Blanco-Campanario, E; de la Cruz-Merino, L; Galán-Brotons, A; Gallegos-Sancho, MI; Murías-Rosales, A; Peláez, I; Pérez-Carrión, R | 1 |
| Audisio, R; Cheung, KL; Collins, K; Morgan, JL; Reed, MW; Robinson, TG; Wyld, L | 1 |
| Bonneterre, J; Delbeuck, X; Kramar, A; Le Rhun, E; Lefeuvre-Plesse, C; Pasquier, F; Skrobala, E | 1 |
| Coates, AS; Colleoni, M; Debled, M; Ejlertsen, B; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Gusterson, B; Mallon, E; Metzger Filho, O; Price, KN; Regan, MM; Thürlimann, B; Viale, G; Winer, EP | 1 |
| Buist, MR; Kenter, GG; van der Velden, J; van Driel, WJ; van Lonkhuijzen, LR; van Meurs, HS | 1 |
| Colleoni, M; Munzone, E | 1 |
| Dowsett, M; Yeo, B | 1 |
| Bibeau, F; Coates, AS; Colleoni, M; Ejlertsen, B; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Gusterson, BA; Lelkaitis, G; MacGrogan, G; Mallon, E; Munzone, E; Price, KN; Thürlimann, B; Viale, G | 1 |
| Abrial, C; Arbre, M; Chollet, P; Devaud, H; Dohou, J; Dubray-Longeras, P; Durando, X; Herviou, P; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Planchat, E; Pouget, M; Van Praagh, I | 1 |
| Bonetti, M; Cole, BF; Gelber, RD; Lazar, AA; Yip, WK | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, V; Demir, L; Dirican, A; Ellidokuz, H; Gumus, Z; Kucukzeybek, B; Kucukzeybek, Y; Salman, T; Sutcu, R; Tarhan, MO; Varol, U; Yildiz, I; Yildiz, Y | 1 |
| Abramovitz, M; Arnould, L; Biasi, MO; Bouzyk, M; Coates, AS; Dell'Orto, P; Gelber, RD; Goldhirsch, A; Gray, KP; Harvey, V; Kammler, R; Leyland-Jones, B; Long, B; Maibach, R; Neven, P; Pagani, O; Price, KN; Rae, JM; Regan, MM; Thürlimann, B; Viale, G; Young, B | 1 |
| Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M | 1 |
| Bayliss, E; Boyle, FM; Campbell, I; Coates, AS; Cuzick, J; Davies, L; Della-Fiorentina, S; Forbes, JF; Gebski, V; Gill, PG; Green, M; Kannourakis, G; Kling, N; Mann, GB; Reaby, L; Saunders, C; Thornton, R; Zdenkowski, N | 1 |
| Alizadeh, AM; Amani Shalamzari, S; Isanejad, A; Khodayari, H; Khodayari, S; Khojastehnjad, N; Khori, V | 1 |
| Chavarri-Guerra, Y; Goss, PE; Liedke, PE; Pritchard, KI; Shepherd, L; Stearns, V; Tu, D | 1 |
| An, HJ; Byun, JH; Chung, SM; Ha, KS; Hong, JH; Jung, SS; Jung, YH; Kang, D; Kim, JS; Lee, GJ; Park, IY; Park, JC; Park, S; Park, WC; Suh, YJ; Won, HS; Woo, IS | 1 |
| Baker, SG; Bonetti, M | 1 |
| Chirgwin, JH; Coates, AS; Colleoni, M; Debled, M; Ejlertsen, B; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Láng, I; Neven, P; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B | 1 |
| Gilarranz, YJ; Lopez-Tarruella, S; Martin, M | 1 |
| Altinok, AY; Altug, T; Azria, D; Bese, NS; Ober, A; Ozsahin, EM; Sut, N; Yildirim, S | 1 |
| Arellano, C; Chatelut, E; Dalenc, F; Filleron, T; Iuliano, L; Marquet, P; Poirot, M; Roché, H; Samadi, M; Silvente-Poirot, S; Voisin, M; Zerbinati, C | 1 |
| Ellis, H; Higgins, M; O'Leary, CG | 1 |
| Baron, P; Beatty, J; Beitsch, P; de Snoo, FA; Dul, CL; Lee, LA; Mislowsky, A; Murray, M; Nash, C; Pellicane, JV; Rotkis, M; Stork-Sloots, L; Whitworth, P | 1 |
| Fitton, JH; Lowenthal, RM; McGuinness, G; Olesen, I; Oliver, LJ; Patel, R; Peterson, GM; Shastri, M; Tocaciu, S | 1 |
| Klinge, CM; Muluhngwi, P | 1 |
| Bodurka, DC; Coleman, RL; Gershenson, DM; Lu, KH; Malpica, A; Sun, CC | 1 |
| Giorgadze, E; Khachidze, N; Tsagareli, M | 1 |
| Brentnall, AR; Cuzick, J; Sasieni, P | 1 |
| Cohen, PR | 1 |
| Ahern, TP; Borgquist, S; Coates, AS; Colleoni, M; Debled, M; Ejlertsen, B; Garber, JE; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Láng, I; Price, KN; Rabaglio, M; Regan, MM; Smith, I; Thürlimann, B; von Moos, R | 1 |
| Bai, Y; Kwok, HF; Mahadevappa, R; McCrudden, CM; Neves, H; Wen, Q; Yuen, HF; Yuen, SM; Zhang, SD | 1 |
| Gaikwad, A; Gonzalez, A; Mathew, L; Nugent, EK; Smith, JA | 1 |
| Dalmau, E; Fernández-Morales, LA; Marín, M; Martinez Vila, C; Oliveres, H; Pardo, JC; Ribera, P; Segui, MA | 1 |
| Ellis, MJ; Goncalves, R; Reinert, T | 1 |
| Hong, N; Kim, SI; Park, S; Rhee, Y; Seo, DH; Sohn, JH; Yoon, HG | 1 |
| Banerjee, S; Della Pepa, C; George, A; Gore, M; Kaye, S; McLachlan, J; Migali, C; Tunariu, N | 1 |
| Balkenende, EME; Beerendonk, CCM; Bos, AME; Cantineau, AEP; Dahhan, T; de Bruin, JP; Fleischer, K; Goddijn, M; Kopeika, Y; Lambalk, CB; Linn, SC; Louwé, LA; Reddy, N; Schats, R; Schipper, I; Smeenk, JMJ; Stoop, D; van der Veen, F; van Golde, RJT; van Wely, M | 1 |
| Alkner, S; Bendahl, PO; Fernö, M; Jensen, MB; Mouridsen, H; Rasmussen, BB; Rydén, L | 1 |
| Armstrong, DK; Bergstrom, J; DeBernardo, R; Fader, AN; Gaillard, S; Jernigan, A; Levinson, KL; Michener, C; Ricci, S; Roche, KL; Rose, PG; Shih, IM; Stone, RL; Tanner, EJ; Wang, TL; Wethingon, S; Yang, B; Zhang, G | 1 |
| He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S | 1 |
| Blok, EJ; Duijm-de Carpentier, M; Kroep, JR; Liefers, GJ; Maartense, E; Meershoek-Klein Kranenbarg, E; Nortier, JWR; Putter, H; Rutgers, EJT; van de Velde, CJH; van den Bosch, J; van Leeuwen-Stok, AE | 1 |
| Ejlertsen, B; Giobbie-Hurder, A; Iversen, BR; Jensen, MB; Kirkegaard, T; Lykkesfeldt, AE; Rasmussen, BB; Reiter, BE | 1 |
| Clayman, E; Huber, KM; Kumar, A; Smith, P | 1 |
| Amoroso, D; Arpino, G; Bernardo, A; Bisagni, G; Carlini, P; Cognetti, F; Cogoni, AA; De Laurentiis, M; De Placido, S; Del Mastro, L; Foglietta, J; Frassoldati, A; Gallo, C; Gori, S; Gravina, A; Lai, A; Laudadio, L; Lauria, R; Lorusso, V; Mocerino, C; Montemurro, F; Moretti, G; Moscetti, L; Nuzzo, F; Perrone, F; Riccardi, F; Rizzo, S; Russo, A; Sarobba, MG; Verusio, C | 1 |
| Dirix, LY | 1 |
| Babu, KG; Bardia, A; Campos-Gomez, S; Carlson, G; Chow, L; Colleoni, M; De Laurentiis, M; Diaz-Padilla, I; El-Saghir, N; Franke, F; Germa, C; Harbeck, N; Hirawat, S; Hughes, G; Hurvitz, SA; Im, SA; Im, YH; Jung, KH; Kuemmel, S; Lee, KS; Liu, MC; Lu, YS; Sohn, J; Tripathy, D; Villanueva Vazquez, R; Wheatley-Price, P | 1 |
| Asher, R; Biasi, OM; Colleoni, M; Dell'Orto, P; Demanse, D; Dolan, S; Hackl, W; JeBailey, L; Kammler, R; Lee, CK; Loi, S; Luen, SJ; Regan, MM; Savas, P; Thuerlimann, B; Viale, G | 1 |
| Arai, E; Ogata, D; Shiomi, Y; Takeuchi, H; Tsuchida, T | 1 |
| Dalenc, F; Roché, H; Sarradin, V; Sibaud, V; Tournier, E | 1 |
| Lu, J; Wu, B; Yang, F; Ye, M | 1 |
| Chang, B; Fan, X; Jiang, X; Kariminia, S; Li, L; Li, Q; Li, T; Li, Y; Wu, S; Zhang, J | 1 |
| Bailey, C; Birkett, J; De Grève, J; De Vos, FYFL; Dean, E; Dirix, L; Goessl, C; Grundtvig-Sørensen, P; Italiano, A; Jerusalem, G; Learoyd, M; Leunen, K; Molife, LR; Plummer, R; Rolfo, C; Rottey, S; Spencer, S; Spicer, J; Verheul, HM | 1 |
| Bonnefoi, H; Coates, AS; Colleoni, M; de Azambuja, E; Del Mastro, L; Di Leo, A; Ejlertsen, B; Gelber, RD; Gianni, L; Giobbie-Hurder, A; Gladieff, L; Goldhirsch, A; Harvey, VJ; Jakobsen, EH; Jassem, J; Jensen, MB; Kralidis, E; Láng, I; Neven, P; Piccart-Gebhart, M; Regan, MM; Rochlitz, C; Ruhstaller, T; Simoncini, E; Spazzapan, S; Thürlimann, B; Tondini, C; Veyret, C; Zaman, K | 1 |
| Churchman, M; Dawson, C; Gourley, C; Herrington, CS; Hollis, RL; Mackean, MJ; Nunes, H; Nussey, F; Rye, T; Stanley, B; Towler, JD; Yan, X | 1 |
| Amir, E | 1 |
| Bandos, H; Brufsky, AM; Chia, SK; Dakhil, SR; Fehrenbacher, L; Geyer, CE; Graham, ML; Jeong, JH; Lembersky, BC; Mamounas, EP; McCarron, EC; Paik, S; Rastogi, P; Seay, TE; Soori, GS; Swain, SM; Wade, JL; Walshe, JM; Wickerham, DL; Wolmark, N | 1 |
| Åvall-Lundqvist, E; Bagge, E; Beiron, U; Malander, S; Rosenberg, P | 1 |
| Dong, S; Feng, F; Qi, L; Sun, C; Tian, J; Wang, X; Yao, Y; Zhang, T; Zhou, C | 1 |
| Clark, BL; Gersch, CL; Gregory, BJ; Hayes, DF; Henry, NL; Hertz, DL; Kamdem, LK; Kidwell, KM; Rae, JM; Stearns, V; Storniolo, AM; Xi, J | 1 |
| Baker, GM; Brown, M; Colleoni, M; Hazra, A; Heng, YJ; Kammler, R; Kensler, KH; Pyle, ME; Regan, MM; Schnitt, SJ; Tamimi, RM; Thürlimann, B; Viale, G | 1 |
| Birzniece, V; Ho, KKY; McLean, M; Reddy, N | 1 |
| Shao, ZM; Yu, KD | 1 |
| Regan, MM; Ruhstaller, T | 1 |
| Arenare, L; Barni, S; Cinieri, S; Daniele, G; De Laurentiis, M; De Maio, E; de Matteis, A; De Placido, S; Del Mastro, L; Di Rella, F; Fabbri, A; Forestieri, V; Gallo, C; Gori, S; Gravina, A; Ibrahim, T; Iodice, G; Landi, G; Lauria, R; Mosconi, AM; Normanno, N; Nuzzo, F; Orditura, M; Pacilio, C; Perrone, F; Piccirillo, MC; Putzu, C; Ribecco, AS; Riccardi, F; Rossi, E; Simeon, V; Tinessa, V | 1 |
| Dempsey, JM; Desta, Z; Gersch, CL; Hayes, DF; Henry, NL; Hertz, DL; Kidwell, KM; Pesch, AM; Rae, JM; Skaar, TC; Stearns, V; Storniolo, AM | 1 |
| Aktas, B; Barry, WT; Carey, LA; Carrasco, E; Casas, M; Cirrincione, CT; De la Haba-Rodríguez, J; Dickler, MN; Furlanetto, J; Garcia-Saenz, JA; Guerrero-Zotano, A; Hahn, O; Hudis, C; Hyslop, T; Loibl, S; Martín, M; Martinez-Jañez, N; Mehta, K; Morales, S; Partridge, A; Rodriguez-Martin, C; Winer, E | 1 |
| Yardley, DA | 1 |
| Chen, J; Fan, Y; He, T; Huang, Q; Li, P; Lv, Q; Wu, Y; Xiang, M; Yang, D; Yang, W; Zhang, X; Zhou, R | 1 |
| Carpi, A; Ferrari, P; Morganti, R; Nicolini, A; Rossi, G | 1 |
| Abdelhamid, T; El Desouky, ED; Khaled, H; Nassar, H; Omran, MA; Rashad, N; Shouman, SA | 1 |
| Ames, MM; Bruinsma, ES; Buhrow, SA; Carter, JM; Cheng, J; Goetz, MP; Hawse, JR; Hoskin, TL; Hou, X; Ingle, JN; Jayaraman, S; Kalari, KR; Kuffel, MJ; McGovern, RM; Monroe, DG; Reid, JM; Reinicke, KE; Safgren, SL; Suman, VJ; Tang, X; Walden, CA; Zeldenrust, MA | 1 |
| Bartlett, JMS; Blok, EJ; Duijm-de Carpentier, M; Hasenburg, A; Hozumi, Y; Kroep, JR; Liefers, GJ; Markopoulos, CJ; Meershoek-Klein Kranenbarg, E; Noordhoek, I; Paridaens, R; Portielje, JEA; Putter, H; Rea, DW; Rutgers, EJT; Seynaeve, C; van de Velde, CJH; Vannetzel, JM | 1 |
| Bergqvist, M; Bethune, A; Bidard, FC; Brain, E; Cabel, L; Cottu, P; Donnadieu, A; Kiavue, N; Lerebours, F; Loirat, D; Pierga, JY; Rodrigues, M; Rosenblum, D; Tanguy, ML | 1 |
| Bonnefoi, H; Castiglione, M; Coates, AS; Colleoni, M; Ejlertsen, B; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Harvey, VJ; Láng, I; Maibach, R; Neven, P; Rabaglio, M; Regan, MM; Ruepp, B; Sun, Z; Thürlimann, B; Wardley, A | 1 |
| Bonnefoi, H; Coates, AS; Cole, BF; Colleoni, M; Di Leo, A; Ejlertsen, B; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Harvey, VJ; Láng, I; Leone, JP; Lin, NU; Neven, P; Rabaglio, M; Regan, MM; Thürlimann, B; Vaz-Luis, I; Wardley, A | 1 |
| Ahn, JH; Cheon, J; Jeong, JH; Jung, KH; Kim, GM; Kim, JE; Kim, SB; Koh, SJ; Lee, KS; Park, IH; Sim, SH; Sohn, J | 1 |
| Almog, B; Azem, F; Cohen, Y; Fouks, Y; Kalma, Y; Shulman, Y | 1 |
| Agostinetto, E; de Azambuja, E; Debien, V; Lambertini, M; Marta, GN; Piccart-Gebhart, M | 1 |
| Blomqvist, C; Faltinová, M; Haanpää, M; Hämäläinen, E; Lyytinen, H; Mattson, J; Tiitinen, A; Vehmanen, L | 1 |
| Cedars, MI; Chien, AJ; Dolezal, M; Juarez-Hernandez, F; Letourneau, J; McCulloch, CE; Mok-Lin, E; Ribeiro, S; Rosen, M; Wald, K; Wang, A | 1 |
| Abdi, E; Aebi, S; Burstein, HJ; Chirgwin, J; Coates, AS; Colleoni, M; Courtois, A; Farah, S; Gavilá, J; Gelber, RD; Goldhirsch, A; Gombos, A; Graas, MP; Hitre, E; Jerusalem, G; Kamby, C; Karlsson, P; Kuroi, K; Loi, S; Loibl, S; Marth, C; Müller, B; Neven, P; O'Reilly, S; Rabaglio, M; Regan, MM; Ribi, K; Ruepp, B; Ruhstaller, T; Simoncini, E; Thompson, A; Viale, G | 1 |
| Amaducci, L; Arpino, G; Ballestrero, A; Barone, C; Bighin, C; Bisagni, G; Bruzzi, P; Campadelli, E; Cognetti, F; De Placido, S; Del Mastro, L; Durando, A; Fabi, A; Frassoldati, A; Garrone, O; Gori, S; Lambertini, M; Mansutti, M; Michelotti, A; Montemurro, F; Moretti, G; Mura, S; Poggio, F; Ponzone, R; Puglisi, F; Sanna, G; Tamberi, S; Urracci, Y | 1 |
| Chang, LT; Chen, CH; Chen, CN; Tam, KW | 1 |
| Gong, S; Hong, K; Liang, JJ; Liu, TY; Qin, KM; Xie, BH; Yan, JJ; Yang, L; Yin, YP; Yu, WL; Zhou, HB | 1 |
| Ng, BP; Park, C; Park, SK; Woo, A | 1 |
| Lu, X; Qian, C | 1 |
| Elancheran, R; Maruthanila, VL; Mirunalini, S | 1 |
| Andersson, M; Buch-Larsen, K; Gillberg, L; Marina, D; Rasmussen, ÅK; Schwarz, P | 1 |
| Balkenende, EME; Beerendonk, CCM; Bos, AME; Cantineau, AEP; Dahhan, T; de Bruin, JP; Fleischer, K; Goddijn, M; Lambalk, CB; Linn, SC; Louwé, LA; Schats, R; Smeenk, JMJ; Stoop, D; van der Veen, F; van Wely, M | 1 |
| Abel, MK; Juarez-Hernandez, F; Letourneau, JM; Mok-Lin, E; Rosen, MP; Wang, A | 1 |
| Acconcia, F | 1 |
| Flaws, JA; Furth, PA; Kang, K; Keegan, G; Muralidaran, V; Rooney, BL; Wang, W; Zou, X | 1 |
| Han, S; Heo, JH; Mehta, S; Park, C; Spencer, JC | 1 |
| Bhaskaran, R; Louis, DM; Nair, LM; Narmadha, MP; Vallonthaiel, AG; Vijaykumar, DK; Yesodharan, J | 1 |
| Choupo, A; Fotsing, SI; Ngo Pambe, JC; Njamen, D; Pieme, CA; Silihe, KK; Yembeau, NL; Zingue, S | 1 |
| Bandos, H; Brufsky, AM; Chia, SK; Dakhil, SR; Fehrenbacher, L; Geyer, CE; Jeong, JH; Lembersky, BC; Mamounas, EP; McCarron, EC; Rastogi, P; Soori, GS; Swain, SM; Wade, JL; Walshe, JM; Wolmark, N | 1 |
| Al Hussein Al Awamlh, B; Barocas, DA; Chang, SS; Cortese, BD; Dusetzina, SB; Luckenbaugh, AN; Penson, DF; Stimson, CJ; Talwar, R | 1 |
| Davidson, NE; Symonds, LK | 1 |
126 review(s) available for letrozole and tamoxifen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[New drugs in metastatic breast cancer--1997].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Diphosphonates; Drug Resistance, Multiple; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Tamoxifen; Taxoids; Triazoles; Zoledronic Acid | 1997 |
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 1997 |
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Belgium; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Severity of Illness Index; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 1999 |
Aromatase inhibitors and their application in breast cancer treatment*.
Topics: Androstenedione; Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Mice; Nitriles; Tamoxifen; Triazoles | 2000 |
Drug and hormone interactions of aromatase inhibitors.
Topics: Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Interactions; Enzyme Inhibitors; Estrogens; Fadrozole; Female; Humans; Letrozole; Male; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Sensitivity and Specificity; Tamoxifen; Triazoles | 1999 |
Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 1999 |
Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 1999 |
Use of aromatase inhibitors in breast carcinoma.
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Design; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Tamoxifen; Triazoles | 1999 |
[Developments of hormonal agents for breast cancer].
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2001 |
Role of anti-aromatase agents in postmenopausal advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2001 |
Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
A summary of second-line randomized studies of aromatase inhibitors.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Tolerance; Enzyme Inhibitors; Estrogen Receptor Modulators; Fadrozole; Female; Humans; Letrozole; Megestrol Acetate; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2001 |
Preliminary data from ongoing adjuvant aromatase inhibitor trials.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles | 2001 |
Antiaromatase agents: evolving role in adjuvant therapy.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
[The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile].
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Follow-Up Studies; Forecasting; Humans; Letrozole; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Triazoles | 2002 |
[Antiestrogen therapy in the treatment of breast neoplasms].
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Forecasting; Humans; Indoles; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Triazoles | 2002 |
Anti-tumor effects of letrozole.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Estrogen Receptor Modulators; Estrogens; Female; Humans; Letrozole; Mastectomy, Segmental; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Salvage Therapy; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
[Present and future of adjuvant hormone therapy in breast cancer: clinical evidence and clinical trials].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2003 |
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays | 2003 |
Emerging role of aromatase inhibitors in the adjuvant setting.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Remodeling; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Quality of Life; Tamoxifen; Triazoles | 2003 |
Safety issues surrounding the use of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Metabolism; Nitriles; Patient Satisfaction; Quality of Life; Safety; Tamoxifen; Triazoles | 2003 |
Should aromatase inhibitors replace tamoxifen?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2003 |
Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2003 |
Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Challenges in the endocrine management of breast cancer.
Topics: Adult; Aged; Anastrozole; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Letrozole; Mastectomy, Segmental; Mice; Middle Aged; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom | 2003 |
[Neoadjuvant endocrine therapy for breast cancer: an overview].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Tamoxifen; Triazoles | 2004 |
[Controversies in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogen Replacement Therapy; Female; Humans; Letrozole; Mastectomy, Segmental; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Triazoles | 2004 |
Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Female; Gene Expression Profiling; Humans; Letrozole; Nitriles; Oligonucleotide Array Sequence Analysis; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Aromatase inhibitors for breast cancer in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2004 |
Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; Drug Interactions; Economics, Pharmaceutical; Female; Forecasting; Geriatrics; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Patient Selection; Postmenopause; Practice Patterns, Physicians'; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles; United States; United States Food and Drug Administration | 2004 |
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Overcoming endocrine therapy resistance by signal transduction inhibition.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Farnesyltranstransferase; Humans; Immunosuppressive Agents; Letrozole; Nitriles; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Tamoxifen; Triazoles | 2004 |
[Aromatase inhibitors in the adjuvant therapy of breast carcinomas].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Patient Care Management; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
Current developments in hormonal therapy of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Triazoles | 2004 |
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Letrozole; Menopause; Neoplasms, Hormone-Dependent; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2004 |
Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Trees; Drug Administration Schedule; Drug Monitoring; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Quality of Life; Safety; Selective Estrogen Receptor Modulators; Social Support; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Aromatase inhibitors and breast cancer: time for a change?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Letrozole; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Evidence-Based Medicine; Female; Humans; Letrozole; Mastectomy, Segmental; Neoadjuvant Therapy; Nitriles; Randomized Controlled Trials as Topic; Receptors, Estrogen; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Changing clinical practice: extending the benefits of adjuvant endocrine therapy in breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Aromatase inhibitors in the management of early breast cancer: optimizing the clinical benefit.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; National Health Programs; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2005 |
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance; Estrogen Receptor Modulators; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Tamoxifen; Time Factors; Triazoles | 2005 |
Aromatase inhibitors for therapy of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Evaluation; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
[Consensus Meeting of the 9th International Conference on Primary Therapy of Early Breast Cancer (St. Gall, January 26-29, 2005)].
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
The aromatase inhibitors in early breast cancer: who, when, and why?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Letrozole; Nitriles; Patient Selection; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Endpoint Determination; Female; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Estrogen Receptor Modulators; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
[Interactions between radiation and hormonal therapy in breast cancer: simultaneous or sequential treatment].
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Models, Animal; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Letrozole; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism; Triazoles; Venous Thrombosis | 2006 |
Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2006 |
Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Topics: Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Neoplasm Staging; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Extended adjuvant therapy with letrozole: reducing the risk of recurrence.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Lymphatic Metastasis; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2006 |
[Introduction of new drug: letrozole, a new non-steroidal aromatase inhibitor for the treatment of postmenopausal women with breast cancer].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Rate; Tamoxifen; Triazoles | 2006 |
Breast cancer (metastatic).
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Progestins; Tamoxifen; Taxoids; Triazoles | 2006 |
Bone safety of aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; Fractures, Bone; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2006 |
Neoadjuvant endocrine therapy in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Goserelin; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Patient Selection; Tamoxifen; Triazoles | 2007 |
Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Tamoxifen; Triazoles | 2007 |
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
[Advancement in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2007 |
The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2007 |
New advances in ovulation induction.
Topics: Anastrozole; Aromatase Inhibitors; Clomiphene; Estrogen Antagonists; Female; Fertility Agents, Female; Gonadotropins; Humans; Infertility, Female; Letrozole; Nitriles; Ovary; Ovulation Induction; Pregnancy; Pregnancy Rate; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Survival Analysis; Tamoxifen; Time Factors; Triazoles | 2007 |
[Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Prognosis; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Reducing the risk of late recurrence in hormone-responsive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Triazoles | 2007 |
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Drug Resistance; Female; Humans; Letrozole; Musculoskeletal Diseases; Nitriles; Postmenopause; Premenopause; Tamoxifen; Thromboembolism; Triazoles | 2007 |
The discovery and mechanism of action of letrozole.
Topics: Aged; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Female; Humans; Letrozole; Middle Aged; Molecular Structure; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Structure-Activity Relationship; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Causality; Chemotherapy, Adjuvant; Comorbidity; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Incidence; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Osteoporosis; Rats; Survival Analysis; Tamoxifen; Triazoles | 2007 |
The patient experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Patient Education as Topic; Postmenopause; Quality of Life; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2007 |
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Postmenopause; Practice Guidelines as Topic; Quality of Life; Risk Assessment; Secondary Prevention; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Assisted reproduction and breast cancer.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cryopreservation; Embryo Transfer; Female; Fertility Agents, Female; Humans; Infertility, Female; Letrozole; Nitriles; Ovulation Induction; Pregnancy; Primary Ovarian Insufficiency; Quality of Life; Reproductive Techniques, Assisted; Tamoxifen; Triazoles | 2007 |
Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Time Factors; Triazoles | 2008 |
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2008 |
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Evidence-Based Medicine; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
A review of the BIG results: the Breast International Group 1-98 trial analyses.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Quality of Life; Tamoxifen; Treatment Outcome; Triazoles; United States | 2008 |
Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse Clinicians; Nurse Practitioners; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Receptors, Estrogen; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2008 |
Neoadjuvant endocrine therapy for breast cancer: past, present and future.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Forecasting; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Patient Selection; Postmenopause; Tamoxifen; Triazoles | 2008 |
Targeting breast cancer with hormonal treatment options.
Topics: Aftercare; Ambulatory Care; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor Modulators; Humans; Information Services; Internet; Letrozole; Nitriles; Nurse Practitioners; Patient Selection; Postmenopause; Practice Guidelines as Topic; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Therapy, Combination; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Never too late: reducing late breast cancer relapse risk.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Europe; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Risk Factors; Tamoxifen; Time Factors; Triazoles | 2008 |
Overcoming recurrence risk: extended adjuvant endocrine therapy.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Lymphatic Metastasis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Research Design; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2008 |
[Adjuvant breast cancer treatment with hormono-radiotherapy].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2009 |
Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Secondary Prevention; Survival Analysis; Tamoxifen; Triazoles; Women's Health | 2009 |
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Estrogens; Female; Humans; Letrozole; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Pyrazoles; Randomized Controlled Trials as Topic; Recurrence; Salvage Therapy; Sulfonamides; Tamoxifen; Triazoles | 2010 |
Fertility preservation in women with breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Counseling; Cryopreservation; Embryo, Mammalian; Female; Fertility; Gonadotropins; Heterozygote; Humans; Infertility, Female; Letrozole; Nitriles; Oocytes; Ovulation Induction; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2010 |
Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Colorectal Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; RANK Ligand; Secondary Prevention; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
When to start an aromatase inhibitor: now or later?
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2011 |
Overview of adjuvant trials of aromatase inhibitors in early breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2011 |
Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2011 |
An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
Topics: Androgens; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone and Bones; Breast Neoplasms; Clinical Trials as Topic; Cytochrome P-450 Enzyme System; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lipids; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2011 |
Approval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Approval; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; United States; United States Food and Drug Administration | 2011 |
[Progress of molecularly targeted therapy for breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Denosumab; Drug Design; Drug Therapy, Combination; Everolimus; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2012 |
Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2013 |
Pharmacogenomics of endocrine therapy in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Genome-Wide Association Study; Humans; Japan; Letrozole; Musculoskeletal Physiological Phenomena; Nitriles; Pharmacogenetics; Phenotype; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2013 |
Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Pharmacological; Breast Neoplasms; Cytochrome P-450 CYP2D6; Female; Humans; Letrozole; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2013 |
Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Letrozole; Long-Term Care; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Drug-Related Side Effects and Adverse Reactions; Estrogen Antagonists; Female; Follow-Up Studies; Fractures, Bone; Humans; Letrozole; Mastectomy, Segmental; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipient.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Awards and Prizes; Breast Neoplasms; Chemotherapy, Adjuvant; Consensus Development Conferences as Topic; Disease-Free Survival; Female; Genes, erbB-2; Humans; Letrozole; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Precision Medicine; Premenopause; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Switzerland; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Obesity and endocrine therapy: host factors and breast cancer outcome.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Nitriles; Obesity; Postmenopause; Predictive Value of Tests; Premenopause; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction.
Topics: Breast Neoplasms; Cryopreservation; Embryo, Mammalian; Female; Humans; Letrozole; Nitriles; Oocytes; Pregnancy; Receptors, Estrogen; Reproductive Techniques, Assisted; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2013 |
The optimal duration and selection of adjuvant endocrine therapy for breast cancer: how long is enough?
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Recurrence; Risk Factors; Tamoxifen; Time Factors; Triazoles | 2014 |
Neoadjuvant chemotherapy in breast cancer: review of literature.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Patient Selection; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2013 |
Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2015 |
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2016 |
Extended adjuvant endocrine therapy in hormone-receptor-positive early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2016 |
Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Exosomes; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MicroRNAs; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Signal Transduction; Tamoxifen; Triazoles | 2017 |
ADJUVANT (HORMONAL) THERAPY AS A CAUSE OF BONE LOSS IN PATIENTS WITH BREAST CANCER (REVIEW OF LITERATURE).
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Osteoporosis; Postmenopause; Premenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2017 |
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Network Meta-Analysis; Nitriles; Receptor, ErbB-2; Tamoxifen; Triazoles | 2017 |
Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: A network meta-analysis.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Neoadjuvant Therapy; Network Meta-Analysis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Zoledronic Acid | 2019 |
Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Humans; Letrozole; Lipids; Network Meta-Analysis; Research Design; Tamoxifen; Toremifene | 2020 |
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Topics: Aminopyridines; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trastuzumab | 2021 |
Fertility preservation for women with breast cancer before chemotherapy: a systematic review and meta-analysis.
Topics: Breast Neoplasms; Cryopreservation; Female; Fertility Preservation; Humans; Letrozole; Oocytes; Ovulation Induction; Tamoxifen | 2022 |
Influence of the anti-oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogens; Female; Humans; Hypothyroidism; Letrozole; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2023 |
127 trial(s) available for letrozole and tamoxifen
| Article | Year |
|---|---|
Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Interactions; Endocrinology; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 1999 |
Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 1999 |
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Humans; Letrozole; Logistic Models; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
Topics: Antineoplastic Agents; Breast Neoplasms; Disease Progression; Double-Blind Method; ErbB Receptors; Estrogen Antagonists; Female; Humans; Letrozole; Logistic Models; Neoadjuvant Therapy; Nitriles; Odds Ratio; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Prostaglandin; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Preoperative Care; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
[Superiority of letrozole compared with tamoxifen as first line therapy of postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group].
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Palliative Care; Postmenopause; Survival Rate; Tamoxifen; Triazoles | 2002 |
Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Estrogen Antagonists; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Receptor, ErbB-2; Switzerland; Tamoxifen; Treatment Outcome; Triazoles; United States | 2003 |
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.
Topics: Antineoplastic Agents; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Nitriles; Postmenopause; Proportional Hazards Models; Survival Rate; Tamoxifen; Triazoles | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Survival Analysis; Tamoxifen; Triazoles | 2003 |
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Double-Blind Method; ErbB Receptors; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Protein Biosynthesis; Proteins; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trefoil Factor-1; Triazoles; Tumor Suppressor Proteins | 2003 |
A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Cross-Over Studies; Drug Costs; Female; Humans; Letrozole; Life Tables; Nitriles; Postmenopause; Quality-Adjusted Life Years; Survival Analysis; Tamoxifen; Triazoles; United States | 2003 |
Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Triazoles | 2004 |
Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Humans; Karnofsky Performance Status; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Prognosis; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Belgium; Body Mass Index; Breast Neoplasms; Data Interpretation, Statistical; Demography; Dyspareunia; Female; Hot Flashes; Humans; Letrozole; Logistic Models; Memory Disorders; Menopause; Middle Aged; Musculoskeletal Diseases; Nitriles; Pain; Patient Selection; Prospective Studies; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Tamoxifen; Time Factors; Triazoles; Urination Disorders; Vaginal Diseases; Withholding Treatment | 2004 |
The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).
Topics: Aged; Aromatase Inhibitors; Biological Availability; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Probability; Reference Values; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation.
Topics: Adult; Breast Neoplasms; Cryopreservation; Embryo, Mammalian; Female; Fertility; Humans; Letrozole; Nitriles; Ovulation Induction; Tamoxifen; Triazoles | 2005 |
Letrozole improves disease-free survival vs tamoxifen in adjuvant treatment of early breast cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial.
Topics: Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunotherapy; Interferon-beta; Interleukin-2; Letrozole; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Triazoles | 2005 |
Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cross-Over Studies; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Quality of Life; Survival Analysis; Tamoxifen; Triazoles | 2005 |
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Incidence; Letrozole; Lymphatic Metastasis; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Health Status; Humans; Letrozole; Middle Aged; Nitriles; Pain; Placebos; Postmenopause; Quality of Life; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Postmenopause; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Secondary Prevention; Survival Rate; Tamoxifen; Triazoles | 2005 |
Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.
Topics: Aged; Anticarcinogenic Agents; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Female; Humans; Letrozole; Markov Chains; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2006 |
The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone Density; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Collagen Type I; Estrogen Receptor Modulators; Female; Humans; Letrozole; Middle Aged; Nitriles; Peptides; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Comorbidity; Disease-Free Survival; Ethnicity; Female; Humans; Letrozole; Mental Health; Middle Aged; Minority Groups; Nitriles; Pain; Patient Compliance; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles; White People | 2006 |
Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Double-Blind Method; ErbB Receptors; Female; Humans; Letrozole; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Prognosis; Receptor, ErbB-2; Survival Analysis; Tamoxifen; Triazoles | 2006 |
Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Letrozole; Mammography; Middle Aged; Nitriles; Pilot Projects; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Estrogen Antagonists; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2007 |
NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-fr
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Staging; Nitriles; Patient Selection; Postmenopause; Tamoxifen; Triazoles | 2006 |
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prognosis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2007 |
Letrozole in advanced breast cancer: the PO25 trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Cross-Over Studies; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Quality of Life; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Placebos; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Markov Chains; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Triazoles | 2008 |
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
Topics: Adult; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Immunohistochemistry; Letrozole; Nitriles; Postmenopause; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2007 |
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Estrogens; Female; Humans; Letrozole; Lipids; Menopause; Middle Aged; Nitriles; Peptide Fragments; Placebos; Procollagen; Single-Blind Method; Tamoxifen; Triazoles | 2007 |
Letrozole in the neoadjuvant setting: the P024 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Female; Humans; Immunohistochemistry; Letrozole; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Survival Analysis; Tamoxifen; Triazoles | 2007 |
Letrozole in the extended adjuvant setting: MA.17.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Quality of Life; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Europe; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles; United States | 2007 |
A decade of letrozole: FACE.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2007 |
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2007 |
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2008 |
Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Gonadal Hormones; Humans; Letrozole; Middle Aged; Nitriles; Premenopause; Prospective Studies; Statistics, Nonparametric; Tamoxifen; Treatment Outcome; Triazoles; Triptorelin Pamoate | 2008 |
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Estrogens; Humans; Kaplan-Meier Estimate; Letrozole; Lymphatic Metastasis; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Patient Acceptance of Health Care; Placebos; Postmenopause; Progesterone; Proportional Hazards Models; Recurrence; Tamoxifen; Triazoles | 2008 |
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Double-Blind Method; Female; Fractures, Bone; Humans; Letrozole; Middle Aged; Nitriles; Patient Compliance; Postmenopause; Tamoxifen; Triazoles | 2008 |
Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Placebos; Quality of Life; Tamoxifen; Triazoles | 2008 |
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Placebos; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Estradiol; Estrone; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Radioimmunoassay; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women.
Topics: Affect; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Letrozole; Middle Aged; Nitriles; Patient Participation; Patient Selection; Postmenopause; Prospective Studies; Quality of Life; Research Design; Sample Size; Surveys and Questionnaires; Tamoxifen; Triazoles | 2008 |
Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme-Linked Immunosorbent Assay; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Tissue Inhibitor of Metalloproteinase-1; Triazoles | 2008 |
Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Prognosis; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Endocrine System; Female; Humans; Ki-67 Antigen; Letrozole; Nitriles; Postmenopause; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Tamoxifen; Triazoles | 2008 |
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Letrozole; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Bone Quality Test (BQT) scores of fingernails in postmenopausal patients treated with adjuvant letrozole or tamoxifen for early breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nails; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
[Lipid metabolism disorders at the breast cancer patients receiving hormonotherapy].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cholesterol, LDL; Dyslipidemias; Estrogen Antagonists; Female; Humans; Letrozole; Lipid Metabolism Disorders; Nitriles; Tamoxifen; Time Factors; Toremifene; Triazoles; Triglycerides | 2009 |
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Dehydroepiandrosterone Sulfate; Diphosphonates; Estradiol; Female; Follicle Stimulating Hormone; Humans; Hydrocortisone; Imidazoles; Letrozole; Luteinizing Hormone; Middle Aged; Nitriles; Postmenopause; Progesterone; Receptors, Estrogen; Tamoxifen; Testosterone; Triazoles; Zoledronic Acid | 2009 |
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Fractures, Bone; Humans; Incidence; Letrozole; Middle Aged; Nitriles; Postmenopause; Risk Factors; Tamoxifen; Triazoles | 2009 |
Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Drug Therapy, Combination; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Postmenopause; Receptors, Estrogen; Research Design; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carcinoma in Situ; Cyclooxygenase 2; Female; Humans; Immunohistochemistry; Letrozole; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Tamoxifen; Tissue Array Analysis; Triazoles | 2009 |
Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Ductal; Cohort Studies; Estrogen Antagonists; Female; Gene Expression Regulation, Neoplastic; Hormone Replacement Therapy; Humans; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2009 |
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Fractures, Bone; Humans; Incidence; Kaplan-Meier Estimate; Letrozole; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Proportional Hazards Models; Tamoxifen; Triazoles | 2009 |
Update of the BIG 1-98 Trial: where do we stand?
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Letrozole; Nitriles; Postmenopause; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2009 |
A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Bone and Bones; Bone Resorption; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2010 |
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Statistics, Nonparametric; Tamoxifen; Triazoles | 2010 |
Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Endocrine System; Humans; Letrozole; Middle Aged; Nitriles; Quality of Life; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition; Cross-Sectional Studies; Female; Humans; International Agencies; Letrozole; Longitudinal Studies; Menopause; Nitriles; Prognosis; Survival Rate; Tamoxifen; Triazoles | 2011 |
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Double-Blind Method; Female; Follow-Up Studies; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Female; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Nitriles; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2011 |
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Menopause; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2012 |
[Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Double-Blind Method; Estrogens; Female; Humans; Letrozole; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Palliative Care; Postmenopause; Progesterone; Prospective Studies; Remission Induction; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles; Ultrasonography | 2011 |
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Australia; Biomarkers, Tumor; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Europe; Female; Humans; Kaplan-Meier Estimate; Letrozole; Neoplasm Recurrence, Local; Neoplasms, Second Primary; New Zealand; Nitriles; North America; Postmenopause; Proportional Hazards Models; Receptors, Steroid; Risk Factors; Selective Estrogen Receptor Modulators; South Africa; South America; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2011 |
Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.
Topics: Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Placebos; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid | 2011 |
Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Lipids; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2012 |
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 CYP2D6; Disease-Free Survival; Drug Administration Schedule; Female; Genotype; Humans; International Cooperation; Kaplan-Meier Estimate; Letrozole; Middle Aged; Nitriles; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Estradiol; Female; Humans; Imidazoles; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Tamoxifen; Triazoles; Zoledronic Acid | 2012 |
Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cognition; Estrogen Antagonists; Female; Humans; Letrozole; Neoplasm Staging; Nitriles; Quality of Life; Tamoxifen; Triazoles | 2012 |
A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Letrozole; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Paclitaxel; Prognosis; Prospective Studies; Survival Rate; Tamoxifen; Trastuzumab; Triazoles; Young Adult | 2012 |
Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy.
Topics: Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Female; Follow-Up Studies; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Mastectomy; Middle Aged; Nitriles; Phosphorylation; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
A new look at tamoxifen: co-administration with letrozole in intrauterine insemination cycles.
Topics: Adult; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Infertility; Insemination, Artificial; Letrozole; Menotropins; Nitriles; Ovulation Induction; Pregnancy; Prospective Studies; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Placebos; Postmenopause; Premenopause; Quality of Life; Survival; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Estrogen Receptor Modulators; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Obesity; Odds Ratio; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Risk Assessment; Risk Factors; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol; Cholesterol, HDL; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Letrozole; Lipids; Lipoprotein(a); Middle Aged; Nitriles; Postmenopause; Tamoxifen; Time Factors; Triazoles | 2012 |
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Collagen Type I; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Postmenopause; Prospective Studies; Tamoxifen; Triazoles | 2014 |
Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Feasibility Studies; Female; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Letrozole; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Ovariectomy; Premenopause; Prognosis; Survival Rate; Tamoxifen; Triazoles | 2014 |
Does patient education work in breast cancer? Final results from the global CARIATIDE study.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Patient Compliance; Patient Education as Topic; Tamoxifen; Triazoles | 2015 |
5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
Topics: Aged; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Diphosphonates; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Male; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2015 |
A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition Disorders; Female; Humans; Letrozole; Memory; Middle Aged; Nitriles; Postmenopause; Psychomotor Performance; Quality of Life; Tamoxifen; Triazoles | 2015 |
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Nitriles; Receptor, ErbB-2; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Data Interpretation, Statistical; Double-Blind Method; Female; Humans; Letrozole; Nitriles; Outcome Assessment, Health Care; Research Design; Tamoxifen; Treatment Outcome; Triazoles | 2016 |
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Early Detection of Cancer; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Hot Flashes; Humans; Letrozole; Middle Aged; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Australia; Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2016 |
New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole - Analyses from NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents; Autonomic Nervous System Diseases; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Multivariate Analysis; Musculoskeletal Diseases; Nitriles; Proportional Hazards Models; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; Vasomotor System | 2016 |
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.
Topics: Aged; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Medication Adherence; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2016 |
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Decision-Making; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gene Expression Profiling; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Mastectomy, Segmental; Middle Aged; Molecular Typing; Neoadjuvant Therapy; Nitriles; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Registries; Tamoxifen; Taxoids; Treatment Outcome; Triazoles; Young Adult | 2017 |
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.
Topics: Aged; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Letrozole; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Proportional Hazards Models; Radiotherapy, Adjuvant; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2017 |
Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Body Mass Index; Breast Neoplasms; Estrogens; Female; Fertility Preservation; Follicle Stimulating Hormone; Humans; Letrozole; Nitriles; Oocytes; Ovulation Induction; Research Design; Socioeconomic Factors; Tamoxifen; Triazoles; Young Adult | 2017 |
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Neoplasm Grading; Nitriles; Nuclear Receptor Coactivator 3; Postmenopause; Prognosis; Tamoxifen; Tissue Array Analysis; Treatment Outcome; Triazoles; Up-Regulation | 2017 |
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Time Factors; Triazoles | 2018 |
Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Aurora Kinase A; Biomarkers; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Denmark; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Letrozole; Nitriles; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Triazoles | 2018 |
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2018 |
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Topics: Administration, Oral; Adult; Aminopyridines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Internationality; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Premenopause; Prognosis; Proportional Hazards Models; Purines; Survival Analysis; Tamoxifen; Treatment Outcome; Young Adult | 2018 |
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Mutation; Neoplasm Recurrence, Local; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen | 2018 |
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Letrozole; Male; Middle Aged; Neoplasm Staging; Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Tamoxifen; Treatment Outcome | 2018 |
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2019 |
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Letrozole; Middle Aged; Multivariate Analysis; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2019 |
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Estrogen Antagonists; Female; Humans; Kaplan-Meier Estimate; Letrozole; Mastectomy; Middle Aged; Postmenopause; Prognosis; Receptors, Androgen; Receptors, Estrogen; Retrospective Studies; Tamoxifen | 2019 |
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Estrogen Antagonists; Female; Humans; Italy; Letrozole; Middle Aged; Ovary; Premenopause; Tamoxifen; Time Factors; Triptorelin Pamoate; Zoledronic Acid | 2019 |
Effects of
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogens; Female; Genotype; Humans; Letrozole; Liver-Specific Organic Anion Transporter 1; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Tamoxifen | 2019 |
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Evaluation Studies as Topic; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Soft Tissue Neoplasms; Survival Rate; Tamoxifen | 2019 |
MONALEESA clinical program: a review of ribociclib use in different clinical settings.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estrogens; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Postmenopause; Progression-Free Survival; Purines; Receptor, ErbB-2; Tamoxifen; Young Adult | 2019 |
Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study.
Topics: Abdominal Pain; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Constipation; Diarrhea; Female; Hand-Foot Syndrome; Humans; Letrozole; Middle Aged; Progression-Free Survival; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2020 |
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Incidence; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2021 |
Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Letrozole; Leuprolide; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Premenopause; Primary Ovarian Insufficiency; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Young Adult | 2021 |
Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Chromatography, Liquid; Estradiol; Female; Humans; Letrozole; Nitriles; Prospective Studies; Tamoxifen; Tandem Mass Spectrometry | 2021 |
Concomitant tamoxifen or letrozole for optimal oocyte yield during fertility preservation for breast cancer: the TAmoxifen or Letrozole in Estrogen Sensitive tumors (TALES) randomized clinical trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cryopreservation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Embryo, Mammalian; Female; Fertility Preservation; Gonadotropins; Humans; Infertility, Female; Letrozole; Oocytes; Ovulation Induction; Tamoxifen; Young Adult | 2021 |
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Estrogens; Female; Humans; Letrozole; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2021 |
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Italy; Letrozole; Mastectomy; Middle Aged; Neoplasm Staging; Postmenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors | 2021 |
Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols.
Topics: Breast Neoplasms; Female; Fertility Preservation; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Letrozole; Multicenter Studies as Topic; Ovulation Induction; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic; Sperm Injections, Intracytoplasmic; Tamoxifen | 2022 |
Hormone concentrations of dominant follicles in the TALES randomized controlled trial comparing letrozole with tamoxifen.
Topics: Estradiol; Female; Follicle Stimulating Hormone; Gonadotropins; Humans; Letrozole; Ovarian Follicle; Tamoxifen | 2022 |
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2023 |
240 other study(ies) available for letrozole and tamoxifen
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model.
Topics: Androstenedione; Animals; Antineoplastic Agents; Aromatase Inhibitors; Cell Division; Fadrozole; Female; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Organ Size; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles; Uterus | 1995 |
Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
Topics: Androstenedione; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Cell Line; Chloramphenicol O-Acetyltransferase; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fibroblast Growth Factors; Fulvestrant; Humans; Letrozole; Luciferases; Mice; Mice, Nude; Nitriles; Ovariectomy; Polymerase Chain Reaction; Receptors, Progesterone; Recombinant Fusion Proteins; RNA, Messenger; Tamoxifen; Transcription, Genetic; Transfection; Transplantation, Heterologous; Triazoles; Tumor Cells, Cultured | 1998 |
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasms, Hormone-Dependent; Nitriles; Organ Size; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles; Tumor Cells, Cultured; Uterus | 1998 |
Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor.
Topics: Animals; Aromatase Inhibitors; Blood Proteins; Dialysis; Dogs; Enzyme Inhibitors; Erythrocytes; Estrogen Antagonists; Humans; Indicators and Reagents; Letrozole; Mice; Nitriles; Plasma; Protein Binding; Rabbits; Rats; Tamoxifen; Triazoles; Ultrafiltration | 1998 |
Intratumoral aromatase model: the effects of letrozole (CGS 20267).
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Mice; Mice, Inbred BALB C; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles; Tumor Cells, Cultured | 1998 |
The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Nitriles; Tamoxifen; Triazoles; Tumor Cells, Cultured | 1998 |
The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
Topics: Analysis of Variance; Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Tamoxifen; Time Factors; Triazoles; Tumor Cells, Cultured | 1999 |
The Twenty-third Annual San Antonio Breast Cancer Symposium.
Topics: Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Estradiol; Estrogen Antagonists; Female; Fluorouracil; Fulvestrant; Humans; Letrozole; Male; Mastectomy; Nitriles; Prognosis; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Use of ErbB-1 and ErbB-2 to select endocrine therapy for breast cancer: will it play in Peoria?
Topics: Antineoplastic Agents; Breast Neoplasms; ErbB Receptors; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Receptor, ErbB-2; Tamoxifen; Triazoles | 2001 |
Aromatase inhibitors and inactivators in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Estrogens; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2001 |
Superior efficacy of letrozole versus tamoxifen as first-line therapy.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2002 |
Pre-operative endocrine therapy for postmenopausal women: when and why?
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Postmenopause; Preoperative Care; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Aromatase and COX-2 expression in human breast cancers.
Topics: Adipocytes; Adult; Aged; Aged, 80 and over; Animals; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cyclooxygenase 2; Dinoprostone; Endothelium; Enzyme Inhibitors; Epithelial Cells; Estrogen Receptor Modulators; Estrogens; Female; Humans; Immunohistochemistry; Isoenzymes; Letrozole; Mammary Neoplasms, Experimental; Membrane Proteins; Mice; Mice, Inbred BALB C; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Prostaglandin-Endoperoxide Synthases; Stromal Cells; Tamoxifen; Triazoles | 2001 |
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Letrozole; Menopause; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2001 |
Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles; United States; United States Food and Drug Administration | 2002 |
Breast cancer studies challenge tamoxifen therapy.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2000 |
New breast cancer drugs expand treatment options.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
Estrogen as therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase II as Topic; Diethylstilbestrol; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estrogens; Female; Humans; Letrozole; Megestrol Acetate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Salvage Therapy; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
Promising results for Arimidex and Femara.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2001 |
The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Topics: Animals; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; In Vitro Techniques; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2002 |
Estrogens, but not androgens, regulate expression and functional activity of oxytocin receptor in rabbit epididymis.
Topics: Androgens; Animals; Aromatase Inhibitors; Blotting, Northern; Blotting, Western; Enzyme Inhibitors; Epididymis; Estradiol; Estrogen Antagonists; Estrogens; Gene Expression Regulation; Hypogonadism; Letrozole; Male; Nitriles; Oxytocin; Rabbits; Receptors, Oxytocin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Testosterone; Triazoles; Triptorelin Pamoate | 2002 |
Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Progestins; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
Current role of endocrine therapy in the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Receptor Modulators; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
Expression of functional estrogen receptors in human fetal male external genitalia.
Topics: Aromatase Inhibitors; Blotting, Western; Cell Division; Cells, Cultured; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Genitalia, Male; Gestational Age; Humans; Immunohistochemistry; Letrozole; Male; Metribolone; Muscle, Smooth; Nitriles; Penis; Polymerase Chain Reaction; Receptors, Androgen; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Testosterone; Testosterone Congeners; Triazoles | 2003 |
A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Female; Humans; Letrozole; Markov Chains; Models, Biological; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Stochastic Processes; Tamoxifen; Triazoles | 2003 |
Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Division; Chemotherapy, Adjuvant; Female; Humans; Ki-67 Antigen; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2003 |
New approaches to the understanding of tamoxifen action and resistance.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Farnesol; Female; Humans; Immunoenzyme Techniques; Letrozole; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; Nitriles; Receptors, Estrogen; Salicylates; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2003 |
Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Canada; Cost-Benefit Analysis; Decision Support Techniques; Enzyme Inhibitors; Humans; Letrozole; Meta-Analysis as Topic; Nitriles; Quality of Life; Tamoxifen; Triazoles | 2003 |
[Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient].
Topics: Adult; Age Factors; Aged; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Immunotherapy; Letrozole; Meta-Analysis as Topic; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Premenopause; Prognosis; Quality of Health Care; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Toremifene; Trastuzumab; Triazoles | 2003 |
Role of biologic markers in patient selection and application to disease prevention.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Biomarkers; Bone Density; Breast Neoplasms; Enzyme Inhibitors; ErbB Receptors; Estradiol; Female; Humans; Letrozole; Nitriles; Patient Selection; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Triazoles | 2003 |
Examining quality of life issues in relation to endocrine therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Making; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Quality of Life; Tamoxifen; Triazoles | 2003 |
Letrozole after tamoxifen for breast cancer--what is the price of success?
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2003 |
Beyond tamoxifen--extending endocrine treatment for early-stage breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2003 |
Searching for the next tamoxifen.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Research; Tamoxifen; Triazoles; United States | 2003 |
The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Cell Line, Tumor; Disease Models, Animal; Drug Administration Schedule; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Use of letrozole as a chemopreventive agent in aromatase overexpressing transgenic mice.
Topics: Animals; Anticarcinogenic Agents; Aromatase; Aromatase Inhibitors; Birth Weight; Female; Hyperplasia; Lactation; Letrozole; Male; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Nitriles; Pregnancy; Receptors, Estrogen; RNA, Messenger; Tamoxifen; Triazoles | 2003 |
Critics question price of success in halted clinical trial of aromatase inhibitor letrozole.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Controlled Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Estrogen Receptor Modulators; Ethics, Research; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Single-Blind Method; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; United States | 2003 |
Hormonal therapy: introduction.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Prognosis; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom | 2003 |
Oxytocin receptor is expressed in the penis and mediates an estrogen-dependent smooth muscle contractility.
Topics: Animals; Aromatase Inhibitors; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogens; Gonadotropin-Releasing Hormone; Humans; Hypogonadism; In Vitro Techniques; Letrozole; Male; Muscle Contraction; Muscle, Smooth; Nitriles; Osmolar Concentration; Oxytocin; Penis; Rabbits; Receptors, Oxytocin; Tamoxifen; Triazoles; Triptorelin Pamoate | 2004 |
Benefit of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Research Design; Tamoxifen; Time Factors; Triazoles | 2004 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2004 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Drugs may improve long-term outcomes after breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2004 |
New treatment boosts outlook for breast cancer survivors.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2004 |
Role of endocrine therapy in the neoadjuvant surgical setting.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Patient Selection; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Humans; Letrozole; Linear Models; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Organ Size; Ovariectomy; Tamoxifen; Transplantation, Heterologous; Triazoles; Uterus | 2004 |
Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer.
Topics: Androstadienes; Angiopoietin-1; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; DNA Primers; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Neovascularization, Pathologic; Nitriles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Tamoxifen; Taxoids; Triazoles; Vascular Endothelial Growth Factor A | 2004 |
Does letrozole have any place in adjuvant setting in breast cancer patients with documented hypercoagulability?
Topics: Aged; Anticoagulants; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Contraindications; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Pulmonary Embolism; Risk; Tamoxifen; Triazoles; Venous Thrombosis; Warfarin | 2004 |
Long-term insurance for breast cancer survivors.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Insurance, Long-Term Care; Letrozole; Nitriles; Tamoxifen; Triazoles | 2004 |
Comment on "Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results" by J.-M. Nabholtz et al.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Letrozole; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Triazoles | 2004 |
Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy.
Topics: Adult; Aged; Anastrozole; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Letrozole; Magnetic Resonance Imaging; Middle Aged; Nitriles; Pamidronate; Pilot Projects; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid | 2004 |
Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
Topics: Animals; Antineoplastic Agents; Aromatase; Body Composition; Breast Neoplasms; Cell Division; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Letrozole; Mice; Mice, Nude; Mice, Transgenic; Nitriles; Ovariectomy; Tamoxifen; Transplantation, Heterologous; Triazoles | 2004 |
A method for making estimates of the benefit of the late use of letrozole in patients completing 5 years of tamoxifen.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Letrozole; Lymph Nodes; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prognosis; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles | 2004 |
Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Budgets; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Female; Humans; Italy; Letrozole; Markov Chains; Megestrol; Models, Economic; National Health Programs; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Letrozole; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Random Allocation; Tamoxifen; Time Factors; Triazoles | 2004 |
Letrozole better than tamoxifen in postmenopausal women.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
[Efforts in the individualization of the adjuvant systemic therapy in breast cancer--ASCO, 2004].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Patient Care Planning; Patient Satisfaction; Patient Selection; Predictive Value of Tests; Quality of Life; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Tamoxifen; Triazoles | 2004 |
Stimulating effects of androgen on proliferation of cultured ovarian germ cells through androgenic and estrogenic actions in embryonic chickens.
Topics: Animals; Chick Embryo; Coculture Techniques; Female; Flutamide; Hormone Antagonists; Immunohistochemistry; Letrozole; Microscopy, Phase-Contrast; Nitriles; Ovary; Ovum; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-kit; Tamoxifen; Testosterone; Triazoles | 2005 |
Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Nitriles; Oligonucleotide Array Sequence Analysis; Tamoxifen; Triazoles; Up-Regulation | 2005 |
Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cryopreservation; Embryo, Mammalian; Estrogen Antagonists; Female; Fertility; Fertilization in Vitro; Humans; Letrozole; Nitriles; Oocytes; Ovulation Induction; Tamoxifen; Triazoles | 2005 |
Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Disease Progression; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Prognosis; Receptor, ErbB-2; Survival Analysis; Tamoxifen; Triazoles | 2005 |
Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Administration Schedule; Enzyme Activation; Estrogen Receptor alpha; Female; Humans; Letrozole; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Nitriles; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays | 2005 |
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Letrozole; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Postmenopause; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays | 2005 |
Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; GRB2 Adaptor Protein; Humans; Letrozole; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Models, Biological; Nitriles; Receptors, Estrogen; Shc Signaling Adaptor Proteins; Signal Transduction; Src Homology 2 Domain-Containing, Transforming Protein 1; Tamoxifen; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2005 |
Aromatase inhibitors: cellular and molecular effects.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Oligonucleotide Array Sequence Analysis; Receptors, Progesterone; Tamoxifen; Triazoles | 2005 |
Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dizziness; Double-Blind Method; Drug Approval; Female; Follow-Up Studies; Headache; Humans; Letrozole; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Skin Diseases; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; United States; United States Food and Drug Administration | 2005 |
Options for preservation of fertility in women.
Topics: Algorithms; Antineoplastic Agents; Breast Neoplasms; Cryopreservation; Drug Therapy, Combination; Embryo, Mammalian; Female; Fertility; Gonadotropins; Humans; Letrozole; Neoplasms; Nitriles; Ovary; Tamoxifen; Transplantation, Heterotopic; Triazoles | 2005 |
Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Estrogen Antagonists; Humans; Inhibitory Concentration 50; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles | 2005 |
Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Endometrial Stromal Tumors; Estrogen Replacement Therapy; Female; Humans; Letrozole; Medroxyprogesterone Acetate; Middle Aged; Nitriles; Pelvic Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Tamoxifen; Triazoles; Uterine Neoplasms | 2006 |
Aromatase inhibitors--a triumph of translational oncology.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Models, Animal; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2005 |
Oral ovulation induction agents combined with low-dose gonadotropin injections and intrauterine insemination: cost- and clinical effectiveness.
Topics: Administration, Oral; Adult; Analysis of Variance; Clomiphene; Cost-Benefit Analysis; Female; Fertility Agents, Female; Humans; Infertility; Injections; Insemination, Artificial; Letrozole; Menotropins; Nitriles; Ovulation Induction; Pregnancy; Pregnancy Rate; Retrospective Studies; Tamoxifen; Triazoles | 2005 |
Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2005 |
Letrozole in postmenopausal hormone-responsive early-stage breast cancer: a viewpoint by Gerald M. Higa.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Resumption of menses with initiation of letrozole after five years of amenorrhea on tamoxifen: caution needed when using tamoxifen followed by aromatase inhibitors.
Topics: Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Menstruation; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Premenopause; Tamoxifen; Triazoles | 2006 |
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2006 |
Letrozole or tamoxifen in early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Data Interpretation, Statistical; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2006 |
Letrozole or tamoxifen in early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Humans; Letrozole; Lymphatic Metastasis; Nitriles; Secondary Prevention; Tamoxifen; Triazoles | 2006 |
Letrozole or tamoxifen in early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2006 |
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor Modulators; Female; Follicle Stimulating Hormone; Humans; Letrozole; Luteinizing Hormone; Middle Aged; Neoplasm Staging; Nitriles; Ovariectomy; Practice Guidelines as Topic; Tamoxifen; Triazoles | 2006 |
Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Estrogen Antagonists; Estrogens; Fees, Pharmaceutical; Female; Follow-Up Studies; Humans; Letrozole; Markov Chains; Middle Aged; Models, Theoretical; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2006 |
Estrogen receptors: role in breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Hormone Replacement Therapy; Humans; Letrozole; Models, Biological; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Management of choroidal metastases from breast carcinomas using aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Choroid Neoplasms; Combined Modality Therapy; Female; Humans; Letrozole; Mastectomy, Radical; Mastectomy, Segmental; Mastectomy, Simple; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Letrozole; Middle Aged; Nitriles; Quality-Adjusted Life Years; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Female; Humans; Letrozole; Markov Chains; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Time Factors; Triazoles; United States | 2006 |
Re: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor Modulators; Female; Humans; Letrozole; Nitriles; Patient Selection; Progesterone; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
The effect of tamoxifen on the pharmacokinetics of letrozole in female rats.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Drug Interactions; Estrogen Antagonists; Female; Half-Life; Letrozole; Molecular Structure; Nitriles; Rats; Rats, Sprague-Dawley; Tamoxifen; Triazoles | 2006 |
Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; British Columbia; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prognosis; Risk Factors; Survival Rate; Tamoxifen; Triazoles | 2007 |
Biotransformation of letrozole in rat liver microsomes: effects of gender and tamoxifen.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biotransformation; Calibration; Chromatography, High Pressure Liquid; Drug Interactions; Female; In Vitro Techniques; Letrozole; Male; Mass Spectrometry; Microsomes, Liver; Nitriles; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sex Characteristics; Spectrophotometry, Ultraviolet; Tamoxifen; Triazoles | 2007 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing | 2006 |
Aromatase and breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Ovariectomy; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
[Correlation of hormone-metabolic status in breast cancer and effectiveness of adjuvant hormone therapy].
Topics: Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; C-Peptide; Chemotherapy, Adjuvant; Estradiol; Female; Humans; Insulin; Insulin Resistance; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Time Factors; Triazoles | 2006 |
Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Belgium; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Markov Chains; Middle Aged; Nitriles; Postmenopause; Proportional Hazards Models; Quality-Adjusted Life Years; Tamoxifen; Triazoles | 2007 |
Focal adhesion kinase and paxillin: novel regulators of brain sexual differentiation?
Topics: Animals; Animals, Newborn; Aromatase; Blotting, Western; Brain; Cells, Cultured; Estradiol; Female; Focal Adhesion Protein-Tyrosine Kinases; Hypothalamus; Immunohistochemistry; Letrozole; Male; Neurites; Nitriles; Paxillin; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Sex Differentiation; Sex Factors; Tamoxifen; Testosterone; Triazoles | 2007 |
Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone Density; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Collagen Type I; Estrogen Receptor Modulators; Female; Fractures, Bone; Humans; Letrozole; Middle Aged; Nitriles; Peptides; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Communication Barriers; Decision Making; Europe; Female; Health Knowledge, Attitudes, Practice; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Selective Estrogen Receptor Modulators; Surveys and Questionnaires; Tamoxifen; Triazoles | 2007 |
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
Topics: Androstadienes; Androstenedione; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Estrogen Receptor alpha; Estrogen Receptor Modulators; Humans; Letrozole; Mice; Mice, Nude; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Tamoxifen; Triazoles; Wortmannin | 2007 |
Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Markov Chains; Middle Aged; Models, Econometric; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2007 |
Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Letrozole; Markov Chains; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; United Kingdom | 2008 |
Sex-specific effects of androgen and estrogen on proliferation of the embryonic chicken hypothalamic neurons.
Topics: Androgens; Animals; Aromatase Inhibitors; Cell Proliferation; Cells, Cultured; Chick Embryo; Estrogens; Female; Flutamide; Hormone Antagonists; Hypothalamus; Letrozole; Male; Neurons; Nitriles; Sex Characteristics; Tamoxifen; Triazoles | 2007 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epothilones; Everolimus; Female; Fluorouracil; Humans; Letrozole; Nitriles; Sirolimus; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2008 |
Joint one-sided and two-sided simultaneous confidence intervals.
Topics: Aromatase Inhibitors; Clinical Trials as Topic; Confidence Intervals; Drug Therapy, Combination; Humans; Letrozole; Models, Statistical; Nitriles; Research Design; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2008 |
Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
MCF-7aro/ERE, a novel cell line for rapid screening of aromatase inhibitors, ERalpha ligands and ERRalpha ligands.
Topics: Anastrozole; Aromatase Inhibitors; Biological Assay; Cell Line, Tumor; Coumarins; ERRalpha Estrogen-Related Receptor; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Fulvestrant; Genes, Reporter; Genistein; Humans; Letrozole; Ligands; Luciferases; Nitriles; Receptors, Estrogen; Response Elements; Tamoxifen; Thiazoles; Transfection; Triazoles | 2008 |
Regression of chronic lymphocytic leukemia with aromatase inhibitor-letrozole?
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Leukemia, Lymphocytic, Chronic, B-Cell; Mastectomy, Segmental; Neoplasms, Multiple Primary; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2009 |
Method to test whether late extended letrozole, rather than self- selection, improves the outcome in patients with breast cancer who have completed 5 years of tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Placebos; Postmenopause; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Reproducibility of Results; Risk Assessment; Risk Factors; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Sonographic evaluation of endothelial function in letrozole and tamoxifen users.
Topics: Aged; Aromatase Inhibitors; Brachial Artery; Breast Neoplasms; Carotid Artery, External; Case-Control Studies; Endothelium, Vascular; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles; Tunica Intima; Tunica Media; Ultrasonography; Vasodilation | 2008 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Lapatinib; Letrozole; Nitriles; Quinazolines; Sirolimus; Tamoxifen; Trastuzumab; Triazoles; Zoledronic Acid | 2009 |
An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Immunohistochemistry; Letrozole; Microarray Analysis; Middle Aged; Nitriles; Patient Selection; Pilot Projects; Predictive Value of Tests; Proto-Oncogene Proteins c-bcl-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
Effects of binary mixtures of estrogen and antiestrogens on Japanese medaka (Oryzias latipes).
Topics: Animals; Drug Interactions; Endocrine Disruptors; Estradiol; Female; Letrozole; Male; Nitriles; Oryzias; Random Allocation; Reproduction; Statistics, Nonparametric; Tamoxifen; Triazoles; Vitellogenins; Water Pollutants, Chemical | 2009 |
Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Topics: Anastrozole; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Humans; Letrozole; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2009 |
Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anemia, Aplastic; Aromatase Inhibitors; Dyskeratosis Congenita; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Flutamide; Gene Expression Regulation, Enzymologic; Hematopoietic Stem Cells; Heterozygote; Humans; Letrozole; Lymphocytes; Male; Mutation; Nitriles; Receptors, Androgen; Tamoxifen; Telomerase; Triazoles | 2009 |
NCCN Guideline update: Breast Cancer Version 1.2004.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Female; Humans; Letrozole; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2004 |
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Letrozole; Nitriles; Pharmacogenetics; Receptors, Estrogen; Tamoxifen; Triazoles | 2010 |
Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2010 |
[A case of recurrent breast cancer with extensive liver metastasis successfully treated with endocrine therapy].
Topics: Androstadienes; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Letrozole; Liver Neoplasms; Medroxyprogesterone; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Toremifene; Triazoles | 2009 |
Introduction to sessions on guidelines and endocrine therapy, the influence of breast screening on number of mastectomies and the challenge between molecular science and traditional dogma in the treatment of breast cancer. Introduction to Session 6.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Mass Screening; Mastectomy; Nitriles; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles; Zoledronic Acid | 2009 |
Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles; Zoledronic Acid | 2009 |
Screening of chemicals with anti-estrogenic activity using in vitro and in vivo vitellogenin induction responses in zebrafish (Danio rerio).
Topics: Animals; Cells, Cultured; Endocrine Disruptors; Estrogen Antagonists; Female; Hepatocytes; Letrozole; Male; Nitriles; Tamoxifen; Toxicity Tests; Triazoles; Vitellogenins; Water Pollutants, Chemical; Zebrafish | 2010 |
Radiotherapy, antihormonal therapy, and personalised medicine.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Letrozole; Nitriles; Precision Medicine; Radiation Injuries; Tamoxifen; Triazoles | 2010 |
[A case of postoperative liver metastasis of mucinous carcinoma of the breast with complete response to sequential administration of FEC75, tamoxifen citrate, and letrozole].
Topics: Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Letrozole; Liver Neoplasms; Mastectomy; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2010 |
EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Breast Neoplasms; Cell Line, Tumor; Cytoprotection; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Humans; Letrozole; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Purines; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Transfection; Triazoles; Xenograft Model Antitumor Assays | 2010 |
Erythrocyte alpha-tocopherol in breast cancer patients treated with letrozol.
Topics: Adult; Aged; Aged, 80 and over; alpha-Tocopherol; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cholesterol; Chromatography, High Pressure Liquid; Cohort Studies; Erythrocytes; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2010 |
The differences in outcome between ATAC and BIG 1-98 suggest efficacy differences between these two nonsteroidal AIs.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Research Design; Tamoxifen; Treatment Outcome; Triazoles | 2010 |
Cognitive changes associated with endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Female; Humans; Letrozole; Memory; Neoplasms, Hormone-Dependent; Nitriles; Prospective Studies; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; United States; Women's Health | 2010 |
Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Chromatography, Liquid; Female; Humans; Letrozole; Middle Aged; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Tandem Mass Spectrometry; Triazoles | 2010 |
Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Letrozole; Models, Statistical; Neoplasms; Nitriles; Outcome Assessment, Health Care; Predictive Value of Tests; Prognosis; Reproducibility of Results; Tamoxifen; Triazoles | 2010 |
Significance of ER-Src axis in hormonal therapy resistance.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Co-Repressor Proteins; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor alpha; Female; Gene Knockdown Techniques; Humans; Letrozole; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Nitriles; Phosphorylation; Pyrimidines; Receptor, ErbB-2; RNA Interference; src-Family Kinases; Tamoxifen; Thiazoles; Transcription Factors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Body Mass Index; Breast Neoplasms; Cohort Studies; Female; Hand Strength; Humans; Letrozole; Middle Aged; Musculoskeletal Diseases; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Syndrome; Tamoxifen; Triazoles | 2011 |
Transcriptional responses in the brain, liver and gonad of Japanese ricefish (Oryzias latipes) exposed to two anti-estrogens.
Topics: Animals; Brain; Dose-Response Relationship, Drug; Endocrine Disruptors; Estrogen Receptor Modulators; Female; Fish Proteins; Gene Expression Profiling; Gonads; Hypothalamo-Hypophyseal System; Letrozole; Liver; Male; Nitriles; Organ Specificity; Oryzias; RNA, Messenger; Sex Characteristics; Tamoxifen; Toxicity Tests; Transcription, Genetic; Triazoles; Vitellogenins; Water Pollutants, Chemical | 2011 |
A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Gene Expression Profiling; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Oligonucleotide Array Sequence Analysis; Proportional Hazards Models; Proto-Oncogene Proteins c-myc; RNA Interference; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
[Significance of HER2 testing in breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Delivery Systems; Female; Humans; Letrozole; Nitriles; Receptor, ErbB-2; Survival Rate; Tamoxifen; Trastuzumab; Triazoles | 2011 |
The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Catalytic Domain; Computer Simulation; Drug Discovery; Female; Humans; Isoenzymes; Kinetics; Letrozole; Microsomes; Models, Molecular; Nitriles; Tamoxifen; Testosterone; Thermodynamics; Triazoles | 2012 |
Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer?
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Female; Humans; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Retrospective Studies; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Transcriptional responses in Japanese medaka (Oryzias latipes) exposed to binary mixtures of an estrogen and anti-estrogens.
Topics: Animals; Biomarkers; Complex Mixtures; Dose-Response Relationship, Drug; Endocrine Disruptors; Endocrine System; Estrogen Receptor Modulators; Estrogens; Ethinyl Estradiol; Female; Gene Expression Profiling; Hypothalamo-Hypophyseal System; Letrozole; Male; Nitriles; Oryzias; Random Allocation; Sex Factors; Tamoxifen; Transcription, Genetic; Triazoles; Water Pollutants, Chemical | 2011 |
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Breast Neoplasms; Female; Hip; Humans; Letrozole; Lumbar Vertebrae; Middle Aged; Multivariate Analysis; Nitriles; Osteoporosis; Postmenopause; Radiography; Randomized Controlled Trials as Topic; Retrospective Studies; Tamoxifen; Triazoles | 2012 |
Choroidal and optic disc metastases from breast cancer and their response to combination pharmacotherapy with tamoxifen, cyclophosphamide hydrate, letrozole, and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Choroid Neoplasms; Cyclophosphamide; Female; Humans; Letrozole; Middle Aged; Nitriles; Optic Disk; Optic Nerve Neoplasms; Retinal Detachment; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Female; Follow-Up Studies; Humans; Letrozole; Nitriles; Receptor, ErbB-2; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Profiling; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Oligonucleotide Array Sequence Analysis; Pyrazoles; Receptor, IGF Type 1; Receptor, Insulin; Tamoxifen; Triazines; Triazoles; Xenograft Model Antitumor Assays | 2011 |
Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Fluorouracil; Genes, Reporter; Humans; Letrozole; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Postmenopause; Premenopause; Tamoxifen; Thymidine Phosphorylase; Triazoles; Xenograft Model Antitumor Assays | 2012 |
Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2012 |
CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6; Female; Glucuronosyltransferase; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Tamoxifen; Triazoles | 2012 |
L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Cancer Vaccines; Cyclophosphamide; Estradiol; Estrogen Antagonists; Female; Interferon-gamma; Interleukin-12; Letrozole; Mammary Neoplasms, Animal; Membrane Glycoproteins; Mice; Mucin-1; Neoplasms, Hormone-Dependent; Nitriles; Random Allocation; Tamoxifen; Th1 Cells; Triazoles | 2012 |
Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Base Sequence; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression; Genes, erbB-1; Humans; Letrozole; Nitriles; Norpregnadienes; Progestins; Promegestone; Receptors, Progesterone; RNA, Messenger; RNA, Neoplasm; Tamoxifen; Testosterone; Triazoles; Tumor Stem Cell Assay | 2013 |
Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Combined Modality Therapy; Female; Letrozole; Nitriles; Pulmonary Fibrosis; Radiation Injuries, Experimental; Rats; Rats, Wistar; Statistics, Nonparametric; Tamoxifen; Triazoles | 2013 |
Introduction of modern endocrine techniques for the production of monosex population of fishes.
Topics: Animals; Aromatase Inhibitors; Estradiol; Female; Fishes; Letrozole; Male; Methyltestosterone; Nitriles; Sex Differentiation; Tamoxifen; Tilapia; Triazoles | 2013 |
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Nucleolus; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Letrozole; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Receptor, ErbB-3; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2012 |
Letrozole: advancing hormone therapy in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Neoplasm Staging; Nitriles; Postmenopause; Quality of Life; Tamoxifen; Triazoles | 2012 |
What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Practice Guidelines as Topic; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles | 2013 |
The aromatase inhibitor letrozole reduces adhesion formation after intraperitoneal surgery in a rat uterine horn model.
Topics: Animals; Aromatase Inhibitors; Female; Foreign-Body Reaction; Letrozole; Nitriles; Peritoneal Cavity; Peritoneum; Postoperative Period; Preoperative Period; Random Allocation; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tamoxifen; Tissue Adhesions; Triazoles; Uterus | 2013 |
Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2013 |
Optimal combination of radiotherapy and endocrine drugs in breast cancer treatment.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; bcl-2-Associated X Protein; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Female; Humans; Letrozole; Nitriles; Proto-Oncogene Proteins c-bcl-2; Radiotherapy Dosage; Tamoxifen; Triazoles; Up-Regulation | 2013 |
Tamoxifen therapy for patients with breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Premenopause; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2013 |
Tamoxifen therapy for patients with breast cancer - Authors' reply.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2013 |
Effects of femara and tamoxifen on proliferation of FM3A cells in culture.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Cell Line, Tumor; Cell Proliferation; Estrogen Antagonists; Female; Letrozole; Mammary Neoplasms, Animal; Mice; Mice, Inbred C3H; Mitotic Index; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2013 |
A UK national survey of breast surgeons on primary endocrine therapy of early operable breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; General Surgery; Health Surveys; Humans; Letrozole; Nitriles; Practice Patterns, Physicians'; Tamoxifen; Triazoles | 2013 |
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Carcinoma, Papillary; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Estrogen Receptor Modulators; Estrogens; Fluorouracil; Gonadotropin-Releasing Hormone; Goserelin; Humans; Kaplan-Meier Estimate; Letrozole; Male; Mastectomy, Modified Radical; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Progesterone; Radiotherapy, Adjuvant; Tamoxifen; Taxoids; Triazoles | 2013 |
Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Doxorubicin; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HEK293 Cells; Humans; Letrozole; MCF-7 Cells; Nitriles; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Triazoles; Ubiquitin-Conjugating Enzymes | 2013 |
Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Biomarkers, Tumor; BRCA1 Protein; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Estrogens; Female; Gene Expression Regulation, Neoplastic; Genetic Markers; Humans; Hydroxyprostaglandin Dehydrogenases; Letrozole; Middle Aged; Nitriles; Receptors, Progesterone; ROC Curve; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Fertility preservation with ovarian stimulation protocols prior to cancer treatment.
Topics: Aromatase Inhibitors; Estrogen Antagonists; Female; Fertility Preservation; Gonadotropins; Humans; Letrozole; Neoplasms; Neoplasms, Hormone-Dependent; Nitriles; Ovulation Induction; Precision Medicine; Tamoxifen; Time-to-Treatment; Triazoles | 2014 |
Symptoms of endocrine treatment and outcome in the BIG 1-98 study.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Incidence; Letrozole; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Nitriles; Proportional Hazards Models; Retrospective Studies; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; Tumor Burden | 2014 |
Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Australia; Breast Neoplasms; Cohort Studies; Comorbidity; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Practice Guidelines as Topic; Premenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; Tumor Burden | 2014 |
Effect of dietary administration of letrozole and tamoxifen on gonadal development, sex differentiation and biochemical changes in common carp (Cyprinus carpio L.).
Topics: Animals; Aromatase Inhibitors; Carps; Estradiol; Estrogen Antagonists; Female; Gonads; Letrozole; Male; Nitriles; Sex Differentiation; Spermatogenesis; Tamoxifen; Triazoles | 2015 |
Tumour grade on core biopsy and evidence of axillary involvement on ultrasound predicts response in elderly co-morbid patients treated with primary hormone therapy for oestrogen receptor positive breast carcinoma.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Axilla; Biopsy, Large-Core Needle; Breast Neoplasms; Female; Humans; Letrozole; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Nitriles; Receptors, Estrogen; Retrospective Studies; Tamoxifen; Triazoles | 2015 |
Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoembryonic Antigen; Cytokines; Disease Progression; Disease-Free Survival; Female; Humans; Immunity, Cellular; Immunotherapy; Interferon-beta; Interleukin-2; Letrozole; Middle Aged; Mucin-1; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Proportional Hazards Models; Selective Estrogen Receptor Modulators; T-Lymphocytes; Tamoxifen; Tissue Polypeptide Antigen; Toremifene; Triazoles | 2014 |
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tamoxifen; Time Factors; Triazoles | 2014 |
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Insulin Receptor Substrate Proteins; Ki-67 Antigen; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; PTEN Phosphohydrolase; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Stathmin; Tamoxifen; Triazoles | 2014 |
Morphological and immunohistochemical analysis in ovaries and fallopian tubes of tamoxifen, letrozole and clomiphene-treated rats.
Topics: Animals; Cell Nucleus; Chromatin; Clomiphene; Epithelium; Fallopian Tubes; Female; Fertility Agents, Female; Immunohistochemistry; Letrozole; Nitriles; Ovary; Ovulation Induction; Rats; Rats, Wistar; Tamoxifen; Triazoles | 2014 |
VAV3 mediates resistance to breast cancer endocrine therapy.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activators; ErbB Receptors; Erlotinib Hydrochloride; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Genetic Variation; Humans; Indazoles; Letrozole; MCF-7 Cells; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-vav; Quinazolines; RNA Interference; RNA, Small Interfering; Tamoxifen; Toremifene; Triazoles | 2014 |
A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Attitude to Health; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Medication Adherence; Middle Aged; Nitriles; Qualitative Research; Quality of Life; Tamoxifen; Triazoles | 2014 |
Is there a role for hormonal therapy in neuroendocrine carcinoma of the breast? A Paradigmatic case report.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Neuroendocrine; Cytodiagnosis; Diagnostic Errors; Female; Humans; Letrozole; Lymphatic Metastasis; Mastectomy; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2014 |
Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Letrozole; Nitriles; Pilot Projects; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Tamoxifen; Triazoles; Tumor Suppressor Protein p53 | 2014 |
Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogens; Female; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Letrozole; Middle Aged; Musculoskeletal Pain; Nitriles; Prospective Studies; Tamoxifen; Triazoles | 2014 |
Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Australia; Breast Neoplasms; Developed Countries; Drug Utilization Review; England; Female; France; Humans; Internationality; Letrozole; Longitudinal Studies; Netherlands; Nitriles; Scandinavian and Nordic Countries; Tamoxifen; Triazoles | 2015 |
Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Receptors, Estrogen; Retrospective Studies; Spain; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Biomarkers, Tumor; BRCA1 Protein; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Flow Cytometry; Gene Expression Profiling; Gene Regulatory Networks; Humans; Immune System Phenomena; Immunoenzyme Techniques; Letrozole; Mammary Neoplasms, Animal; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Nitriles; Oligonucleotide Array Sequence Analysis; Precancerous Conditions; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tamoxifen; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
[Effect of sex inversion in embryos of domestic chicken (Gallu gallus domesticus) by influence of letrozole and tamoxifen].
Topics: Animals; Aromatase Inhibitors; Chick Embryo; Chickens; Chromosome Mapping; Estrogen Antagonists; Estrogen Receptor alpha; Female; Gene Expression; Genetic Loci; Gonadal Dysgenesis; Humans; Letrozole; Male; Nitriles; Ovary; Prophase; Protein Interaction Mapping; Sex Chromosomes; Sex Differentiation; Tamoxifen; Testis; Triazoles | 2014 |
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Culture Techniques; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MCF-7 Cells; Models, Biological; Nitriles; Tamoxifen; Triazoles | 2015 |
Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Gonadotropin-Releasing Hormone; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Premenopause; Receptors, Estrogen; Response Evaluation Criteria in Solid Tumors; Tamoxifen; Triazoles | 2015 |
Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Depressive Disorder; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Nitriles; Population Surveillance; Proportional Hazards Models; Retrospective Studies; Risk; Taiwan; Tamoxifen; Trastuzumab; Triazoles | 2015 |
Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cross-Sectional Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Letrozole; Middle Aged; Nitriles; Paclitaxel; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2015 |
Healthcare professionals' preferences for surgery or primary endocrine therapy to treat older women with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Attitude of Health Personnel; Breast Neoplasms; Female; Geriatrics; Humans; Letrozole; Mastectomy; Nitriles; Oncology Nursing; Patient Preference; Receptors, Estrogen; Surgeons; Surveys and Questionnaires; Tamoxifen; Triazoles; United Kingdom | 2015 |
Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Female; Goserelin; Granulosa Cell Tumor; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Ovarian Neoplasms; Ovariectomy; Radiotherapy, Adjuvant; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Salpingectomy; Tamoxifen; Triazoles | 2015 |
Picking the optimal endocrine adjuvant treatment for pre-menopausal women.
Topics: Age Factors; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Goserelin; Humans; Letrozole; Nitriles; Ovary; Premenopause; Tamoxifen; Triazoles | 2015 |
Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Patient Selection; Prognosis; Tamoxifen; Time Factors; Triazoles | 2015 |
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Estradiol; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Prognosis; Retrospective Studies; Survival Rate; Tamoxifen; Triazoles | 2015 |
The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study.
Topics: Adiponectin; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Composition; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Leptin; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2016 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles | 2016 |
MicroRNA-206, let-7a and microRNA-21 pathways involved in the anti-angiogenesis effects of the interval exercise training and hormone therapy in breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Combined Modality Therapy; Exercise Therapy; Female; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; MicroRNAs; Muscle, Skeletal; Neovascularization, Pathologic; Nitriles; Signal Transduction; Tamoxifen; Triazoles | 2016 |
Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Female; Hormone Replacement Therapy; Humans; Letrozole; Male; Mastectomy; Middle Aged; Neoplasms, Second Primary; Nitriles; Prognosis; Receptor, ErbB-2; Republic of Korea; Tamoxifen; Trastuzumab; Treatment Outcome; Triazoles | 2016 |
Evaluating Markers for Guiding Treatment.
Topics: Age Factors; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Body Mass Index; Breast Neoplasms; Clinical Decision-Making; Decision Support Techniques; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Letrozole; Logistic Models; Lymphatic Metastasis; Nitriles; Predictive Value of Tests; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles; Tumor Burden | 2016 |
Aromatase inhibitors decrease radiation-induced lung fibrosis: Results of an experimental study.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Female; Letrozole; Nitriles; Pulmonary Fibrosis; Radiation Injuries, Experimental; Radiotherapy; Rats; Rats, Wistar; Tamoxifen; Triazoles | 2016 |
Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study.
Topics: Adult; Aged; Androstadienes; Aromatase; Aromatase Inhibitors; Biomarkers; Body Mass Index; Breast Neoplasms; Cholestanes; Cholesterol; Feasibility Studies; Female; Gas Chromatography-Mass Spectrometry; Hormones; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Oxidative Stress; Oxysterols; Pilot Projects; Prognosis; Prospective Studies; Reproducibility of Results; Signal Transduction; Tamoxifen; Triazoles | 2017 |
The Effect of Undaria pinnatifida Fucoidan on the Pharmacokinetics of Letrozole and Tamoxifen in Patients With Breast Cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Herb-Drug Interactions; Humans; Letrozole; Middle Aged; Nitriles; Phytotherapy; Polysaccharides; Tamoxifen; Triazoles; Undaria | 2018 |
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Leuprolide; Maintenance Chemotherapy; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Nitriles; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Survival Rate; Tamoxifen; Triazoles; Watchful Waiting; Young Adult | 2017 |
Estimating efficacy in trials with selective crossover.
Topics: Antineoplastic Agents; Binomial Distribution; Biostatistics; Breast Neoplasms; Clinical Trials as Topic; Computer Simulation; Cross-Over Studies; Disease-Free Survival; Female; Humans; Letrozole; Likelihood Functions; Models, Statistical; Nitriles; Proportional Hazards Models; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2017 |
Melasma treatment: A novel approach using a topical agent that contains an anti-estrogen and a vascular endothelial growth factor inhibitor.
Topics: Administration, Topical; Anastrozole; Androstadienes; Aromatase Inhibitors; Estrogens; Female; Genetic Predisposition to Disease; Humans; Hyperpigmentation; Letrozole; Male; Melanosis; Neovascularization, Pathologic; Nitriles; Pregnancy; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; Ultraviolet Rays; Vascular Endothelial Growth Factor A | 2017 |
The prognostic significance of Cdc6 and Cdt1 in breast cancer.
Topics: Animals; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; DNA Replication; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MCF-7 Cells; Mice; Nitriles; Nuclear Proteins; Prognosis; RAW 264.7 Cells; Receptors, Estrogen; Survival Analysis; Tamoxifen; Triazoles; Up-Regulation | 2017 |
Evaluation of Active Hexose Correlated Compound (AHCC) in Combination With Anticancer Hormones in Orthotopic Breast Cancer Models.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Humans; Letrozole; MCF-7 Cells; Mice; Nitriles; Polysaccharides; Tamoxifen; Triazoles | 2017 |
Fulvestrant plus LHRH analogues in male with synchronous breast and prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Estradiol; Fulvestrant; Gonadotropin-Releasing Hormone; Humans; Letrozole; Male; Neoplasms, Multiple Primary; Nitriles; Prostatic Neoplasms; Tamoxifen; Triazoles | 2017 |
Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer.
Topics: Anastrozole; Breast Neoplasms; Humans; Letrozole; Negative Results; Postmenopause; Receptors, Estrogen; Tamoxifen | 2017 |
Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Chemotherapy, Adjuvant; Fatty Liver; Female; Humans; Incidence; Letrozole; Lipids; Middle Aged; Nitriles; Propensity Score; Retrospective Studies; Tamoxifen; Triazoles | 2017 |
The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Carcinoma; Female; Humans; Letrozole; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Ovarian Neoplasms; Receptors, Estrogen; Recurrence; Retreatment; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles; Young Adult | 2017 |
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Female; Humans; Letrozole; Medical Overuse; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2017 |
The Impact of Perioperative Hormonal Therapy for Breast Cancer on Transverse Rectus Abdominis Myocutaneous Flap Abdominal Complications.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Incisional Hernia; Letrozole; Mammaplasty; Middle Aged; Myocutaneous Flap; Odds Ratio; Rectus Abdominis; Retrospective Studies; Risk Factors; Surgical Wound Infection; Tamoxifen; Treatment Outcome | 2018 |
Adjuvant aromatase inhibition: more options for patients.
Topics: Anastrozole; Androstadienes; Aromatase; Breast Neoplasms; Humans; Letrozole; Tamoxifen | 2018 |
Metastatic cutaneous apocrine carcinoma: a multidisciplinary approach incorporating endocrine therapy.
Topics: Antineoplastic Agents, Hormonal; Apocrine Glands; Carcinoma; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Pleural Neoplasms; Radiotherapy, Adjuvant; Sweat Gland Neoplasms; Tamoxifen | 2018 |
Acute Generalized Exanthematous Pustulosis Induced by Docetaxel and Recurrent With Letrozole: A Case Report.
Topics: Acute Generalized Exanthematous Pustulosis; Adrenal Cortex Hormones; Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; Docetaxel; Female; Humans; Letrozole; Middle Aged; Tamoxifen; Treatment Outcome | 2018 |
Economic Evaluation of Letrozole for Early Breast Cancer in a Health Resource-Limited Setting.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; China; Cost-Benefit Analysis; Female; Health Resources; Humans; Letrozole; Neoplasm Recurrence, Local; Postmenopause; Quality-Adjusted Life Years; Tamoxifen | 2018 |
Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
Topics: Age of Onset; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Postmenopause; Prospective Studies; Tamoxifen; Treatment Outcome | 2018 |
Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; CA-125 Antigen; Cystadenocarcinoma, Serous; Female; Humans; Letrozole; Megestrol Acetate; Membrane Proteins; Middle Aged; Neoplasm Grading; Ovarian Neoplasms; Predictive Value of Tests; Receptors, Estrogen; Retrospective Studies; Tamoxifen | 2019 |
Competing risks of extended adjuvant aromatase inhibitors.
Topics: Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Humans; Letrozole; Postmenopause; Tamoxifen | 2019 |
Pattern of endocrine treatment for epithelial ovarian cancer in the Southeast medical region of Sweden: a population-based study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Carcinoma, Ovarian Epithelial; Cohort Studies; Estrogen Antagonists; Fallopian Tube Neoplasms; Female; Humans; Letrozole; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Sweden; Tamoxifen; Treatment Outcome | 2019 |
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.
Topics: Androstadienes; Aromatase Inhibitors; Bone and Bones; Bone Density; Bone Remodeling; Breast Neoplasms; Female; Gene Deletion; Genetic Association Studies; Genotype; Glucuronosyltransferase; Humans; Letrozole; Middle Aged; Minor Histocompatibility Antigens; Pharmacogenetics; Postmenopause; Tamoxifen | 2019 |
Disparate Effect of Aromatization on the Central Regulation of GH Secretion by Estrogens in Men and Postmenopausal Women.
Topics: Aromatase Inhibitors; Cross-Over Studies; Estradiol; Estrogen Antagonists; Female; Human Growth Hormone; Humans; Letrozole; Male; Middle Aged; Pituitary Gland; Postmenopause; Tamoxifen | 2019 |
Comparison of Time-Dependent Contralateral Breast Cancer Incidence Requires Comparable Lengths of Follow-Up.
Topics: Breast Neoplasms; Female; Follow-Up Studies; Humans; Incidence; Letrozole; Neoplasms, Second Primary; Postmenopause; Tamoxifen | 2019 |
Reply to K.-D. Yu et al.
Topics: Breast Neoplasms; Female; Follow-Up Studies; Humans; Letrozole; Postmenopause; Tamoxifen | 2019 |
A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Female; Humans; Immunotherapy; Letrozole; Male; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen; Toremifene | 2020 |
Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer.
Topics: Animals; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Letrozole; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Receptors, Estrogen; Tamoxifen; Xenograft Model Antitumor Assays | 2020 |
Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cohort Studies; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptors, Estrogen; Reproducibility of Results; Risk Assessment; Tamoxifen | 2020 |
Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Piperazines; Prognosis; Prospective Studies; Pyridines; Receptor, ErbB-2; Survival Rate; Tamoxifen; Thymidine Kinase | 2020 |
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial.
Topics: Adult; Aged; Breast Neoplasms; Estrogen Receptor alpha; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2021 |
Effects of letrozole or tamoxifen coadministered with a standard stimulation protocol on fertility preservation among breast cancer patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fertility Preservation; Humans; Infertility, Female; Letrozole; Oocytes; Ovulation Induction; Retrospective Studies; Tamoxifen; Young Adult | 2021 |
Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents; Apoptosis; Biological Products; Breast Neoplasms; Cell Proliferation; Down-Regulation; Estrogen Receptor alpha; Humans; Letrozole; MCF-7 Cells; Molecular Docking Simulation; Protein Binding; Proteolysis; Raloxifene Hydrochloride; Reactive Oxygen Species; Sesterterpenes; Signal Transduction; Structure-Activity Relationship; Tamoxifen | 2022 |
Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study.
Topics: Aged; Anastrozole; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Sectional Studies; Female; Humans; Letrozole; Male; Medicare; Quality of Life; Retrospective Studies; Tamoxifen; United States | 2022 |
Efficacy, Safety, and Prognosis of Sequential Therapy with Tamoxifen and Letrozole versus Letrozole Monotherapy for Breast Carcinoma.
Topics: Breast Neoplasms; Cholesterol, HDL; Female; Humans; Letrozole; Postmenopause; Prognosis; Retrospective Studies; Tamoxifen | 2022 |
Topics: Anastrozole; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carica; Catechin; Chlorogenic Acid; Cyclophosphamide; Estrogen Receptor Modulators; Estrogens; Female; Humans; Letrozole; Ligands; Molecular Docking Simulation; Paclitaxel; Quercetin; Tamoxifen; Trastuzumab | 2022 |
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen | 2022 |
Esr1 but Not CYP19A1 Overexpression in Mammary Epithelial Cells during Reproductive Senescence Induces Pregnancy-Like Proliferative Mammary Disease Responsive to Anti-Hormonals.
Topics: Animals; Aromatase; Epithelial Cells; Estrogen Receptor alpha; Estrogens; Female; Gene Expression; Letrozole; Mammary Glands, Animal; Mice; Pregnancy; Tamoxifen | 2023 |
Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Medicare; Nitriles; Tamoxifen; United States | 2023 |
Unchartered waters: Significance of fall in Ki67 index after short-term preoperative endocrine therapy in early breast cancers.
Topics: Breast Neoplasms; Estrogens; Female; Humans; Ki-67 Antigen; Letrozole; Tamoxifen | 2023 |
Breast cancer cell growth arrest and chemopreventive effects of Passiflora edulis Sims (Passifloraceae) ethanolic leaves extract on a rat model of mammary carcinoma.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Antioxidants; Carcinoma; Ethanol; Letrozole; Passiflora; Passifloraceae; Plant Extracts; Rats; Rats, Wistar; Tamoxifen | 2023 |
Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.
Topics: Aged; Anastrozole; Cost Savings; Drug Costs; Drugs, Generic; Humans; Imatinib Mesylate; Letrozole; Medicare Part D; Prescription Drugs; Tamoxifen; United States | 2023 |
Are we there yet? Optimal duration of endocrine therapy in women with postmenopausal early-stage hormone receptor-positive breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Postmenopause; Tamoxifen | 2023 |